Erdatinib formulations and infiltration systems for intravesical administration

The intravesical drug delivery system with osmotic pressure-driven openings and biocompatible elastomers addresses the limitations of oral erdafitinib formulations by achieving controlled and sustained release in the bladder, enhancing local treatment efficacy for bladder cancer.

CN119072311APending Publication Date: 2024-12-03TARIS BIOMEDICAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034691.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-18
Filing Date
2023-02-17
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current erdafitinib formulations for bladder cancer treatment are limited to oral administration, which may not provide optimal therapeutic effects due to systemic side effects and require multiple dosing, while existing intravesical delivery systems face challenges in controlled and sustained drug release.

Method used

An intravesical drug delivery system using an elongated body with osmotic pressure-driven openings for erdafitinib release, incorporating biocompatible elastomers like silicone or thermoplastic polyurethane, and a drug formulation comprising erdafitinib L-lactate, allowing for controlled and sustained drug release directly into the bladder.

Benefits of technology

The system achieves a zero-order release profile of erdafitinib, providing effective local treatment for bladder cancer with reduced systemic side effects and improved therapeutic efficacy by maintaining consistent drug levels in the bladder for extended periods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072311A_ABST
    Figure CN119072311A_ABST
Patent Text Reader

Abstract

Provided herein are solid pharmaceutical compositions comprising an L-lactate salt of Erdatinib; processes for preparing such formulations; and drug delivery systems comprising such formulations, including systems for intravesical administration.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 311,855, filed on February 18, 2022, the contents of which are hereby incorporated by reference in their entirety.

[0003] Reference to an electronic sequence listing

[0004] The contents of the electronic sequence listing (761662002140seqlisting.xml; size: 53,009 bytes; and creation date: February 15, 2023) are incorporated herein by reference in their entirety. Background Art

[0005] The present disclosure is generally in the field of pharmaceutical formulations and drug-device combination products, and more particularly relates to erdafitinib-based formulations and systems for intravesical administration of such formulations.

[0006] Erdafitinib (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine) is a potent pan-FGFR kinase inhibitor that binds to FGFR1, FGFR2, FGFR3, and FGFR4 and inhibits their enzymatic activity. Erdafitinib has been found to inhibit FGFR phosphorylation and signaling and reduce cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdafitinib has demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.

[0007] Currently, erdafitinib It is available as a film-coated tablet for oral administration and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have a susceptible fibroblast growth factor receptor FGFR3 or FGFR2 genetic alteration and have progressed during or after at least one line of prior platinum-containing chemotherapy (including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy).

[0008] U.S. Patent No. 10,898,482 to Broggini and International Patent Application Publication No. WO 2020 / 201138 to De Porre describe certain erdafitinib formulations and methods of treatment.

[0009] Examples of intravesical drug delivery systems are described in U.S. Pat. Nos. 8,679,094 to Cima et al., 9,017,312 to Lee et al., 9,107,816 to Lee et al., and 9,457,176 to Lee et al. In some embodiments, the intravesical system includes a water-permeable shell defining a drug reservoir lumen containing a solid or semisolid drug formulation, and in vivo release of the drug occurs by diffusion of water from the bladder into the drug reservoir lumen to dissolve the drug, and then osmotic pressure buildup in the drug reservoir lumen drives the dissolved drug out of the drug reservoir lumen through a release hole.

[0010] U.S. Patent No. 10,286,199 to Lee et al. discloses a system in which a drug is released from a housing made of a first wall structure that is impermeable to the drug and a hydrophilic second wall structure that is permeable to the drug. U.S. Patent No. 10,894,150 to Lee also discloses a system in which a drug is released from a housing made of a first wall structure that is impermeable to the drug and a second wall structure that is permeable to the drug. Summary of the invention

[0011] In one aspect, the present invention provides an intravesical drug delivery system, the intravesical drug delivery system comprising an elongated body configured for intravesical insertion into a patient's body and a drug formulation disposed in the elongated body, the drug formulation comprising erdafitinib (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine) or a pharmaceutically acceptable salt thereof, in particular erdafitinib (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine) L-lactate. In some embodiments, the drug delivery system is configured to release erdafitinib from one or more openings in the elongated body driven by osmotic pressure. In some embodiments, erdafitinib is present in the form of a mono-L-lactate. In some embodiments, the elongated body includes a biocompatible elastomer. In some embodiments, the biocompatible elastomer includes silicone or thermoplastic polyurethane. In some embodiments, the biocompatible elastomer includes silicone. In some embodiments, the biocompatible elastomer includes a platinum-cured silicone elastomer. In some embodiments, at least one of the one or more openings in the elongated body is located in the side wall of the elongated body. In some embodiments, at least one of the one or more openings in the elongated body is located at the first end and / or the opposite second end of the elongated body. In some embodiments, the drug delivery system has a single opening, which is located at a position between the first end and the opposite second end of the elongated body in the side wall of the elongated body. In some embodiments, one or more openings have a diameter of about 100 μm to about 200 μm. In some embodiments, one or more openings have a diameter of about 150 μm.

[0012] In some embodiments, the drug delivery system is configured to release Erdafitinib through one or more openings in the elongated body by osmotic pressure. In some embodiments, the elongated body includes an annular wall structure defining a drug reservoir lumen, and the drug formulation is disposed in the drug reservoir lumen. In some embodiments, the annular wall structure has a thickness of about 0.1 mm to about 0.5 mm. In some embodiments, the annular wall structure has a thickness of about 0.2 mm.

[0013] In some embodiments, the drug delivery system further comprises a first end plug positioned at the first end of the annular wall structure and a second end plug positioned at the second end of the annular wall structure. In some embodiments, one or more openings in the elongated body of the drug delivery system comprise a single hole in the annular wall structure, and the elongated body is configured to release Erdafitinib through the hole. In some embodiments, the elongated body is configured to release Erdafitinib through a microchannel formed instantaneously at one or both end regions of the annular wall structure. In some embodiments, the system is configured to release Erdafitinib at an average rate of 1 mg / day to 10 mg / day, particularly 1 mg / day to 10 mg / day of Erdafitinib free base equivalents. In some embodiments, the system is configured to release Erdafitinib at an average rate of 1 mg / day to 6 mg / day. In some embodiments, the system is configured to release Erdafitinib at an average rate of 2 mg / day to 4 mg / day. In some embodiments, the system is configured to release Erdafitinib at an average rate of 4 mg / day. In some embodiments, the system is configured to release Erdafitinib at an average rate of 2 mg / day. In some embodiments, the system is configured to release Erdafitinib with a zero order release profile. In some embodiments, the system is configured to release Erdafitinib for up to about 30 days. In some embodiments, the system is configured to release Erdafitinib for up to about 90 days. In some embodiments, the system comprises 500 mg Erdafitinib (free base equivalent).

[0014] In an embodiment, the drug delivery system is capable of elastically deforming between a relatively straight deployment shape suitable for insertion through the patient's urethra and into the patient's bladder and a retention shape suitable for keeping the system in the bladder. In some embodiments, the drug delivery system is capable of elastic deformation and includes a tube having two opposing free ends, which are guided away from each other when the system is in a low-profile deployment shape and are guided toward each other when the system is in a relatively expanded retention shape. In some embodiments, the system includes an elastically deformable elongated body having two opposing free ends, which are located within the boundaries of a biovoid-like expanded retention shape. In some embodiments, the elongated body also includes a retention frame lumen. In some embodiments, the system also includes a nitinol wire disposed in the retention frame lumen.

[0015] On the other hand, a pharmaceutical composition or a drug delivery system comprising the pharmaceutical composition is provided herein, wherein the pharmaceutical composition comprises a lactate of erdafitinib, in particular an L-lactate of erdafitinib and at least one pharmaceutical excipient. In some embodiments, at least one pharmaceutical excipient includes or is selected from a solubilizer, a binder, a diluent (filler), a wetting agent, a disintegrant, a glidant, a lubricant, a formaldehyde scavenger, an osmotic agent, or any combination thereof. In some embodiments, at least one pharmaceutical excipient includes or is selected from a binder, a diluent (filler), a glidant, a lubricant, or any combination thereof.

[0016] In some embodiments, the binder comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone (PVP), vinyl pyrrolidone-vinyl acetate (PVP-VA), or a combination thereof. In some embodiments, the binder is present in the pharmaceutical formulation at a total concentration of about 1 wt % to about 30 wt %, about 5 wt % to about 20 wt %, or about 10 wt % to about 15 wt %.

[0017] In some embodiments, the diluent (filler) includes microcrystalline cellulose, silicified microcrystalline cellulose, calcium hydrogen phosphate or a combination thereof. In some embodiments, the diluent (filler) is present in the pharmaceutical preparation at a total concentration of about 5% by weight to about 30% by weight, about 10% by weight to about 30% by weight or about 10% by weight to about 20% by weight.

[0018] In some embodiments, the glidant comprises hydrophilic colloidal silicon dioxide or hydrophobic colloidal silicon dioxide.In some embodiments, the glidant is present in the pharmaceutical formulation at a total concentration of about 0.05 wt % to about 1 wt %, about 0.1 wt % to about 0.5 wt %, or about 0.25 wt %.

[0019] In some embodiments, the lubricant comprises magnesium stearate or sodium stearyl fumarate or polyethylene glycol. In some embodiments, the lubricant comprises magnesium stearate or sodium stearyl fumarate. In some embodiments, the lubricant comprises magnesium stearate. In some embodiments, the lubricant is present in the pharmaceutical formulation at a total concentration of about 0.05% by weight to about 5% by weight, about 1% by weight to about 5% by weight, or about 2.5%.

[0020] In some embodiments, the pharmaceutical composition or the drug delivery system comprising the pharmaceutical composition comprises an intragranular composition or intragranular fraction and an extragranular composition or extragranular fraction. In some embodiments, the intragranular composition or fraction comprises erdafitinib or a pharmaceutically acceptable salt thereof, in particular a lactate of erdafitinib, such as erdafitinib L-lactate. In some embodiments, the intragranular composition or fraction comprises erdafitinib or a pharmaceutically acceptable salt thereof, in particular a lactate of erdafitinib, such as erdafitinib L-lactate, and at least one intragranular excipient, and the extragranular composition or extragranular fraction comprises at least one extragranular excipient. In some embodiments, at least one intragranular excipient and at least one extragranular excipient do not include a common pharmaceutical excipient. In some embodiments, at least one intragranular excipient comprises an intragranular binder. In some embodiments, the intragranular binder comprises hydroxypropyl methylcellulose. In some embodiments, at least one extragranular excipient comprises one or more of an extragranular binder, an extragranular filler (diluent), an extragranular glidant, and an extragranular lubricant. In some embodiments, the extragranular binder includes vinyl pyrrolidone-vinyl acetate. In some embodiments, the extragranular diluent (filler) includes microcrystalline cellulose, silicified microcrystalline cellulose or a combination thereof. In some embodiments, the extragranular glidant includes or is colloidal silicon dioxide (hydrophilic). In some embodiments, the extragranular lubricant includes magnesium stearate or sodium stearyl fumarate or polyethylene glycol. In some embodiments, the extragranular lubricant includes magnesium stearate or sodium stearyl fumarate. In some embodiments, the extragranular lubricant includes or is magnesium stearate. In some embodiments, at least one extragranular excipient includes filler and binder, particularly microcrystalline cellulose and vinyl pyrrolidone-vinyl acetate, particularly wherein the weight of filler and binder: weight ratio is 1: 1.

[0021] In some embodiments, the pharmaceutical composition or a drug delivery system comprising the pharmaceutical composition comprises Erdafitinib L-lactate at a concentration of 60% to 91% by weight. In some embodiments, the pharmaceutical composition or a drug delivery system comprising the pharmaceutical composition comprises Erdafitinib L-lactate at a concentration of 60% to 80% by weight. In some embodiments, Erdafitinib L-lactate is present in the pharmaceutical formulation at a concentration of 70% by weight.

[0022] In some embodiments, the pharmaceutical composition or a drug delivery system comprising the pharmaceutical composition comprises Erdafitinib L-lactate in the form of a plurality of mini-tablets. In some embodiments, the pharmaceutical composition is in the form of about 10 to about 100 mini-tablets. In some embodiments, the pharmaceutical composition comprises a mini-tablet having a total length of about 14.5 cm to about 15 cm, and / or (b) the formulation comprises a mini-tablet of about 920 mg to about 965 mg. In some embodiments, the pharmaceutical composition comprises a mini-tablet having a total length of about 14.5 cm to about 15 cm, and / or (b) the formulation comprises a mini-tablet of about 920 mg to about 950 mg.

[0023] In some embodiments, the pharmaceutical composition comprising erdafitinib L-lactate is in the form of a tablet having a hardness of at least about 100 N. In some embodiments, the tablet has a hardness of about 150 N to about 250 N. In some embodiments,

[0024] Tablet has a hardness of about 175N to about 225N. In some embodiments, tablet has a thickness of about 3.2mm to about 3.6mm. In some embodiments, tablet is a mini tablet in the form of a solid cylinder, and this solid cylinder has a cylindrical axis, a cylindrical side, a circular end face perpendicular to the cylindrical axis, a diameter through the circular end face and a length along the cylindrical side. In some embodiments, the length of mini tablet exceeds the diameter of mini tablet, to provide a mini tablet with an aspect ratio (length: diameter) greater than 1:1. In some embodiments, mini tablet has a diameter of 1.0mm to 3.2mm or 1.5mm to 3.1mm. In some embodiments, mini tablet has a diameter of 2.5mm to 2.7mm. In some embodiments, mini tablet has a length of 3.0mm to 3.5mm. In some embodiments, mini tablet has a quality of 22mg to 24mg.

[0025] In another aspect, a method for preparing the pharmaceutical composition in tablet form is provided, the method comprising: (a) preparing an intragranular solid composition comprising erdafitinib L-lactate and at least one intragranular pharmaceutical excipient; (b) combining the intragranular solid composition with at least one extragranular pharmaceutical excipient to form a blend; and (c) tableting the blend to form a solid pharmaceutical composition. In some embodiments, (a) at least one intragranular pharmaceutical excipient comprises at least one intragranular binder; and (b) at least one extragranular pharmaceutical excipient comprises an extragranular binder, an extragranular filler (diluent), an extragranular glidant, and an extragranular lubricant. In some embodiments, the intragranular solid composition is prepared by a fluidized bed granulation process. In some embodiments, at least one intragranular binder comprises hydroxypropyl methylcellulose. In some embodiments, at least one extragranular binder comprises vinyl pyrrolidone-vinyl acetate (PVP VA). In some embodiments, at least one extragranular filler (diluent) comprises microcrystalline cellulose. In some embodiments, the extragranular filler (diluent) further comprises a second extragranular filler (diluent) comprising silicified microcrystalline cellulose. In some embodiments, the extragranular glidant comprises or is colloidal silicon dioxide (hydrophilic). In some embodiments, the extragranular lubricant comprises or is magnesium stearate. In some embodiments, the extragranular lubricant comprises sodium stearyl fumarate. In some embodiments, the extragranular lubricant comprises polyethylene glycol. In some embodiments, at least one extragranular excipient comprises a filler and a binder, particularly microcrystalline cellulose and vinyl pyrrolidone-vinyl acetate, particularly wherein the weight: weight ratio of filler to binder is 1: 1. In some embodiments, the ejection force is less than about 1000N. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Detailed description is set forth with reference to the accompanying drawings. The use of the same reference numerals may indicate similar or identical items. Various embodiments may utilize elements and / or components other than those shown in the accompanying drawings, and some elements and / or components may not be present in various embodiments. The elements and / or components in the accompanying drawings are not necessarily drawn to scale.

[0027] Figure 1A is a plan view of one embodiment of a drug delivery system in accordance with the present disclosure in a curled, retained shape.

[0028] Figure 1B yes Figure 1A A cross-sectional view of one embodiment of a drug delivery system shown in FIG. 1 taken along line BB.

[0029] Figure 2 is a schematic diagram illustrating the operation of one embodiment of an osmotic drug delivery system according to the present disclosure.

[0030] Figure 3 is a perspective view of one embodiment of a mini-tablet form of a pharmaceutical formulation according to the present disclosure.

[0031] Figure 4 Single dose erdafitinib exposure in plasma from nude rats bearing subcutaneous UM-UC-1 tumors or orthotopic UM-UC-1 tumors is shown. Exposure levels were measured in plasma from naive nude rats, nude rats bearing orthotopic bladder or subcutaneous UM-UC-1 tumors. Rats were administered a single IVES (1 hour infusion) or oral dose of erdafitinib at the indicated dose levels. Individual data points are shown, with the mean at each time point represented by a horizontal line. IVES, intravesical; PO or po, oral; sc, subcutaneous.

[0032] Figure 5 The effect of erdafitinib on ERK1 / 2 phosphorylation in orthotopic bladder UM-UC-1 tumors is shown. Individual pERK and total ERK levels were measured in UM-UC-1 orthotopic bladder tumors from nude rats treated with vehicle or a single IVES (1 hour instillation) or oral dose of erdafitinib at the indicated dose levels. pERK and total ERK levels are reported as ratios (pERK / ERK) relative to the mean of the vehicle group at the corresponding time point, with the exception of the 120 hour time point, where the values ​​were normalized to the 48 hour vehicle group. Individual data points are shown, with the mean at each time point represented by a horizontal line. N=2-6 / group; ERK, extracellular signal-regulated kinase; IVES, intravesical; pERK, phosphorylated extracellular signal-regulated kinase; PO or po, oral.

[0033] Figure 6 The size of an orthotopic bladder UC tumor example relative to a control bladder at 14 days post-implantation is shown. Formalin was used to fix tissue samples after necropsy. UC, urothelial carcinoma; NBTII, rat Nara Bladder Tumor No. 2 cells; T24, human bladder carcinoma cells.

[0034] Figure 7 Schematic diagram of perfusion experiments in athymic rats with UM-UC-1 implanted into the bladder wall.

[0035] Figure 8The percent weight change of athymic, bladder-catheterized rats bearing orthotopic UM-UC-1 bladder tumors is shown. The values ​​of the figure are expressed as the mean ± SEM of 10 to 13 animals in each group. The concentrations quoted in the legend are the nominal target urine concentrations. Statistical analysis was performed by two-way ANOVA followed by Bonferroni multiple comparison test using Graph Pad Prism (version 8.3.0). There was no statistically significant difference when the percent weight change of the erdafitinib (0.5 μg / mL, 1.0 μg / mL, and 5.0 μg / mL) treatment groups was compared to the percent weight change of the vehicle control group. SEM, standard error of the mean.

[0036] Fig. 9 The mean percentage reduction in tumor weight after calculation of tumor-free bladder weight is shown. Values ​​(Groups 1-4) are expressed as mean ± SEM of 10 to 13 animals in each group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparison test using Graph Pad Prism (Version 8.3.0). Conc, concentration; SEM, standard error of the mean.

[0037] Fig.10 The percentage change in body weight of athymic, bladder-catheterized rats carrying orthotopic RT-112 bladder tumors is shown. Values ​​are expressed as mean ± SEM of 2 to 14 animals in each group. The concentrations quoted in the legend are nominal target urine concentrations. Statistical analysis was performed by two-way ANOVA followed by Bonferroni multiple comparison test using Graph Pad Prism (version 8.3.0). When the percentage change in body weight of the Erdafitinib (0.5 μg / mL, 1.0 μg / mL, and 5.0 μg / mL) treatment groups was compared with the percentage change in body weight of the vehicle control group except Group 4 on Day 11, there was no statistically significant difference (*p<0.05). SEM, standard error of the mean.

[0038] Fig.11 The effect of intravesical erdafitinib exposure on tumor growth, as measured by change in total bladder weight in athymic nude rats bearing orthotopic RT-112 bladder tumors, is shown. Values ​​(Groups 1-5) are expressed as mean ± SEM of 2 to 14 animals in each group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparison test using Graph Pad Prism (Version 8.3.0). *p<0.05. Conc, concentration; SEM, standard error of the mean; ns, not significant.

[0039] Fig. 12A and Fig. 12BShown are plasma ( Fig. 12A ) and intravesical ( Fig. 12B ) concentration. Bladder instillation of Erdafitinib solution (0.1 mg / mL, 0.1 mL / hour, cumulative dose 0.72 mg) was performed over 72 hours. Concentrations are expressed as the average daily urine concentration in ng / mL.

[0040] Fig.13 Shown are the mean erdafitinib urine concentrations in pigs following intravesical instillation of erdafitinib at a constant rate of 12.5 mL / hour for 6 consecutive days (2 animals) and 8 consecutive days (3 animals). All voided urine was collected at 24 hour intervals on day 6 or day 8. Conc., concentration; SD, standard deviation.

[0041] Fig.14 Shown are mean erdafitinib plasma concentrations in pigs following intravesical instillation of erdafitinib at a constant rate of 12.5 mL / hour for 6 consecutive days (2 animals) and 8 consecutive days (3 animals). Blood samples were collected daily from study day 1 to day 8. SD, standard deviation.

[0042] Fig.15 Screening results of material penetration are shown. O, permeable; Δ, almost impermeable; X, impermeable. a The variability between replicates is high.

[0043] Figure 16A-16C Schematic diagram of the infiltration system design with holes + end plugs is shown. Fig.16A A cross-sectional side view of one embodiment of a device having a preformed sidewall aperture and two constraining end plugs is provided. Fig. 16B A plan view of one embodiment of a device having a preformed sidewall aperture and two constraining end plugs is provided. Fig. 16C A cross-sectional side view of an end of one embodiment of a device having a constraining end plug and a microchannel formed through the end plug is provided.

[0044] Fig.17 The IVR curve of Prototype 4, permeation (orifice + end plug), 0.2 mm wall, Erdafitinib L-lactic acid, tablet (20 wt% water-insoluble excipients) is shown. Erda, Erdafitinib; IVR, in vitro release; SU, simulated urine; FBE, free base equivalent.

[0045] Fig.18 IVR curves for Prototype 5, permeation (orifice + end plug), 0.2 mm wall, Erdafitinib L-lactic acid, tablet (water soluble excipients) are shown. Erda, Erdafitinib; IVR, in vitro release; SU, simulated urine; FBE, free base equivalent.

[0046] Fig.19 The mean urine concentration versus time curves for prototypes 4 to 5 in miniature pigs are summarized.

[0047] Figure 20A-20B The solubility of erdafitinib L-lactate in water at 37°C as a function of pH (wherein the pH was adjusted using HCl / NaOH solution) is shown ( Fig. 20A ), and the solubility of erdafitinib L-lactate in simulated urine at 37°C as a function of pH (mg / mL) ( Fig. 20B ).

[0048] Fig.21 An overview of the reaction for the synthesis of erdafitinib mono-L-lactate (JNJ-42756493-AFK) from erdafitinib substrate (JNJ-42756493-AAA) is shown. DETAILED DESCRIPTION

[0049] In some embodiments, a solid formulation of Erdafitinib containing a high concentration of Erdafitinib is provided, which is designed for intravesical drug delivery and controlled and extended drug release when deployed in the bladder. In some embodiments, when used in an intravesical drug delivery system, the solid Erdafitinib formulation is further customized for large-scale manufacturing and provides the structural and chemical integrity of the solid formulation (particularly tablets). An improved intravesical drug delivery system and a drug delivery method are also provided. In a specific embodiment, the system is configured for intravesical insertion and sustained drug delivery, preferably providing a zero-order release rate of a therapeutically effective amount of a drug (particularly Erdafitinib).

[0050] Described herein are erdafitinib formulations and release systems tailored for intravesical drug delivery to take advantage of this route of administration. Such formulations can provide controlled drug release rates and extended drug release profiles when formulated into solid forms and administered in suitable intravesical drug delivery systems. Further provided are systems capable of delivering erdafitinib at effective release rates for local treatment of bladder cancer.

[0051] In a specific embodiment, the drug delivery system described herein is a drug-device combination, which consists of a device component (particularly an intravesical device) and a drug component (particularly an erdafitinib formulation, such as an erdafitinib tablet).

[0052] Erdafitinib formulations and tablets

[0053] In one aspect, erdafitinib lactate, particularly erdafitinib L-lactate, particularly erdafitinib mono-L-lactate is disclosed. For example, it can be used to locally deliver / administer erdafitinib to a patient. In an embodiment, a pharmaceutical composition comprising erdafitinib lactate (particularly erdafitinib L-lactate) and one or more excipients is provided. In some embodiments, the pharmaceutical composition is in the form of a tablet, particularly in the form of a mini-tablet.

[0054] In one aspect, the present disclosure provides erdafitinib formulations, particularly erdafitinib tablets suitable for use in the disclosed intravesical drug delivery systems. In particular, a pharmaceutical tablet comprising a salt form of erdafitinib (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine) is provided. After the drug delivery system is inserted into the bladder, the drug is released from the system into the bladder. In one aspect, for example, the drug delivery system can be operated as an osmotic pump that produces a continuous release of the drug into the bladder over an extended period of time as the drug is released from the tablet in the system.

[0055] In order to increase or maximize the amount of drug that can be stored in and released from the disclosed drug delivery system, the pharmaceutical tablet may have a relatively high Erdafitinib content (by weight). This relatively high weight portion of Erdafitinib in the pharmaceutical tablet is accompanied by a reduced or low weight portion of excipients, which may be necessary for tablet manufacturing and system assembly and drug use considerations. For the purposes of this disclosure, terms such as "weight portion", "weight percentage" and "percentage by weight" with respect to any drug or API (active pharmaceutical ingredient) are directed to the drug or API in the form in which it is used (whether in free base form, free acid form, salt form or hydrate form). For example, a pharmaceutical tablet having 90% (90 wt %) of a drug or excipient in salt form by weight may include less than 90 wt % of the drug in free base form.

[0056] The Erdafitinib pharmaceutical tablets disclosed herein include Erdafitinib content and excipient content. The pharmaceutical content may include one or more forms of Erdafitinib, such as a free base or a salt form, and the excipient content may include one or more excipients. Particular embodiments include salts of Erdafitinib, more particularly Erdafitinib lactate, such as a mono-L-lactate of Erdafitinib. The term "excipient" is known in the art, and representative examples of excipients that can be used in the disclosed pharmaceutical tablets may include, but are not limited to, ingredients such as binders, lubricants, glidants, disintegrants, solubilizers, colorants, fillers or diluents, wetting agents, stabilizers, formaldehyde scavengers, coatings and preservatives or any combination thereof, as well as other ingredients that facilitate the manufacture, storage or use of pharmaceutical tablets.

[0057] In an embodiment, the erdafitinib pharmaceutical tablet comprises erdafitinib in salt form. In one aspect, the erdafitinib pharmaceutical tablet may comprise greater than or equal to 50% by weight of erdafitinib L-lactate, the remainder of the weight comprising excipients that facilitate the preparation and use of pharmaceutical tablets, such as lubricants, binders, and stabilizers. In an embodiment, the erdafitinib pharmaceutical tablet comprises erdafitinib in salt form. In one aspect, the erdafitinib pharmaceutical tablet may comprise greater than or equal to 50% by weight of erdafitinib L-lactate, the remainder of the weight comprising excipients that facilitate the preparation and use of pharmaceutical tablets, such as lubricants, fillers, binders, and glidants. Alternatively, the erdafitinib pharmaceutical tablet may contain greater than or equal to 40 wt%, greater than or equal to 45 wt%, greater than or equal to 50 wt%, greater than or equal to 55 wt%, greater than or equal to 60 wt%, greater than or equal to 65 wt%, greater than or equal to 70 wt%, greater than or equal to 75 wt%, greater than or equal to 80 wt%, greater than or equal to 85 wt%, or greater than or equal to 90 wt% of the erdafitinib L-lactate. In one aspect, the pharmaceutical tablet may contain 50 wt% to 90 wt%, 65 wt% to 85 wt%, 70 wt% to 80 wt%, such as 70 wt%, 75 wt%, or 80 wt% of erdafitinib in the form of its L-lactate salt, based on the total weight of the tablet.

[0058] In an embodiment, the erdafitinib in the erdafitinib pharmaceutical tablet is in the form of an L-lactate salt of erdafitinib. The properties of the L-lactate salt of erdafitinib that make it advantageous for use in the disclosed osmotic system include its high solubility, its stability, and its ability to act as an osmotic agent without the need for the addition of an osmotic agent.

[0059] Erdafitinib formulations with a range of excipient combinations (both intragranular and extragranular) are provided in Tables 2, 9, 13 and 16 in the Examples. In particular, Table 16 lists formulation concepts 1-5. Concepts 1-5 are formulation embodiments encompassed by the present disclosure.

[0060] In some embodiments, the solid pharmaceutical composition comprises: (a) 70 weight % of erdafitinib L-lactate; (b) 1.43 weight % of hydroxypropyl methylcellulose; (c) 9.30 weight % of microcrystalline cellulose; (d) 7.22 weight % of silicified microcrystalline cellulose; (e) 9.30 weight % of vinyl pyrrolidone-vinyl acetate (PVP VA); (f) 0.25 weight % of colloidal silicon dioxide (hydrophilic); and (g) 2.5 weight % of magnesium stearate, wherein these weight percentages are relative to the entire solid pharmaceutical composition. In some embodiments, the solid pharmaceutical composition comprises: (a) 70 wt% of erdafitinib L-lactate, intragranular; (b) 1.43 wt% of hydroxypropyl methylcellulose, intragranular; (c) 9.30 wt% of microcrystalline cellulose, extragranular; (d) 7.22 wt% of silicified microcrystalline cellulose, extragranular; (e) 9.30 wt% of vinylpyrrolidone-vinyl acetate (PVP VA), extragranular; (f) 0.25 wt% of colloidal silicon dioxide (hydrophilic), extragranular; and (g) 2.5 wt% of magnesium stearate, extragranular. In some embodiments, the solid pharmaceutical composition is a tablet. In some embodiments, the formulation is Concept 1.

[0061] In some embodiments, the solid pharmaceutical composition comprises: (a) 70 weight % of erdafitinib L-lactate; (b) 1.43 weight % of hydroxypropyl methylcellulose; (c) 12.91 weight % of microcrystalline cellulose; (d) 12.91 weight % of vinyl pyrrolidone-vinyl acetate (PVP VA); (e) 0.25 weight % of colloidal silicon dioxide (hydrophilic); and (f) 2.5 weight % of magnesium stearate, wherein these weight percentages are relative to the entire solid pharmaceutical composition. In some embodiments, the solid pharmaceutical composition comprises: (a) 70 wt% erdafitinib L-lactate, intragranular; (b) 1.43 wt% hydroxypropyl methylcellulose, intragranular; (c) 12.91 wt% microcrystalline cellulose, extragranular; (d) 12.91 wt% vinyl pyrrolidone-vinyl acetate (PVP VA), extragranular; (e) 0.25 wt% colloidal silicon dioxide (hydrophilic), extragranular; and (f) 2.5 wt% magnesium stearate, extragranular. In some embodiments, the solid pharmaceutical composition is a tablet. In some embodiments, the formulation is Concept 2.

[0062] In some embodiments, the solid pharmaceutical composition comprises: (a) 70 weight % of erdafitinib L-lactate; (b) 1.43 weight % of hydroxypropyl methylcellulose; (c) 12.91 weight % of microcrystalline cellulose; (d) 12.91 weight % of vinyl pyrrolidone-vinyl acetate (PVP VA); (e) 0.25 weight % of colloidal silicon dioxide (hydrophilic); and (f) 2.5 weight % of sodium stearyl fumarate, wherein these weight percentages are relative to the entire solid pharmaceutical composition. In some embodiments, the solid pharmaceutical composition comprises: (a) 70 wt% erdafitinib L-lactate, intragranular; (b) 1.43 wt% hydroxypropyl methylcellulose, intragranular; (c) 12.91 wt% microcrystalline cellulose, extragranular; (d) 12.91 wt% vinylpyrrolidone-vinyl acetate (PVP VA), intragranular; (e) 0.25 wt% colloidal silicon dioxide (hydrophilic), extragranular; and (f) 2.5 wt% sodium stearyl fumarate, extragranular. In some embodiments, the solid pharmaceutical composition is a tablet. In some embodiments, the formulation is Concept 3.

[0063] In some embodiments, the solid pharmaceutical composition comprises: (a) 60 weight % of erdafitinib L-lactate; (b) 1.23 weight % of hydroxypropyl methylcellulose; (c) 18.01 weight % of microcrystalline cellulose; (d) 18.01 weight % of vinyl pyrrolidone-vinyl acetate (PVP VA); (e) 0.25 weight % of colloidal silicon dioxide (hydrophilic); and (f) 2.5 weight % of magnesium stearate, wherein these weight percentages are relative to the entire solid pharmaceutical composition. In some embodiments, the solid pharmaceutical composition comprises: (a) 60 wt% erdafitinib L-lactate, intragranular; (b) 1.23 wt% hydroxypropyl methylcellulose, intragranular; (c) 18.01 wt% microcrystalline cellulose, extragranular; (d) 18.01 wt% vinyl pyrrolidone-vinyl acetate (PVP VA), extragranular; (e) 0.25 wt% colloidal silicon dioxide (hydrophilic), extragranular; (f) 2.5 wt% magnesium stearate, extragranular. In some embodiments, the solid pharmaceutical composition is a tablet. In some embodiments, the formulation is Concept 4.

[0064] In some embodiments, the solid pharmaceutical composition comprises: (a) 80 weight % of erdafitinib L-lactate; (b) 1.63 weight % of hydroxypropyl methylcellulose; (c) 7.81 weight % of microcrystalline cellulose; (d) 7.81 weight % of vinyl pyrrolidone-vinyl acetate (PVP VA); (e) 0.25 weight % of colloidal silicon dioxide (hydrophilic); and (f) 2.5 weight % of magnesium stearate, wherein these weight percentages are relative to the entire solid pharmaceutical composition. In some embodiments, the solid pharmaceutical composition comprises: (a) 80 wt% erdafitinib L-lactate, intragranular; (b) 1.63 wt% hydroxypropyl methylcellulose, intragranular; (c) 7.81 wt% microcrystalline cellulose, extragranular; (d) 7.81 wt% vinyl pyrrolidone-vinyl acetate (PVP VA), extragranular; (e) 0.25 wt% colloidal silicon dioxide (hydrophilic), extragranular; and (f) 2.5 wt% magnesium stearate, extragranular. In some embodiments, the solid pharmaceutical composition is a tablet. In some embodiments, the formulation is Concept 5.

[0065] In embodiments, the Erdafitinib drug and excipients are selected and the tablets are formulated to allow the drug to be released from the tablets. In embodiments, Erdafitinib is formulated in a pharmaceutical composition to be sterilized, within or outside the drug delivery system, without causing substantial or deleterious changes in the chemical or physical composition of the drug tablet, which would otherwise render the drug tablet unsuitable for delivery of Erdafitinib as described herein. In one aspect, the Erdafitinib drug and excipients are selected for their suitability for a sterilization process. In one embodiment, the drug delivery system comprising the drug tablet is sterilized as a whole. In particular, the drug delivery system comprising the drug tablet is sterilized by gamma radiation.

[0066] In one aspect, the size and shape of the Erdafitinib drug tablet can be configured for use with an indwelling drug delivery system including an intravesical drug delivery system disclosed herein. For example, the Erdafitinib drug tablet can be a "mini-tablet" that is generally smaller in size than a conventional tablet, which can allow the drug tablet contained in the system to be inserted into a cavity (such as the bladder) through a natural body cavity (such as the urethra). The Erdafitinib tablet can be coated or uncoated. In particular, uncoated tablets can work well in combination with the disclosed delivery system.

[0067] An example of a microtablet is shown in Figure 3 , which illustrates a microtablet 312 having a circular flat end face 326 and a cylindrical side wall 328.

[0068] In embodiments, the drug tablet for intravesical insertion can be in the form of a solid cylinder, which has a cylindrical axis, a cylindrical side, a circular end face perpendicular to the cylindrical axis, a diameter through the circular end face and a length along the cylindrical side face. In cylindrical form, each mini-tablet can have a length (L) exceeding its diameter (D) so that the mini-tablet has an aspect ratio (L:D) greater than 1:1. For example, the aspect ratio (L:D) of each mini-tablet can be 1.6, 1.5, 1.4, 1.3, 1.2, 1.1 or the scope of the value between these aspect ratios. The embodiment of mini-tablet can have a cylindrical diameter of 1.0mm to 3.2mm, or 1.5mm to 3.1mm, or 2.0mm to 2.7mm, or 2.5mm to 2.7mm. In some respects, mini-tablet can have a diameter of 2.4mm to 2.8mm. In some aspects, the mini-tablet may have a length of 1.7 mm to 4.8 mm, or 2.0 mm to 4.5 mm, or 2.8 mm to 4 mm, or 3 mm to 3.5 mm. In some aspects, the mini-tablet may have a length of 3.0 mm to 3.4 mm.

[0069] The API used in the solid tablet formulation can be erdafitinib, which is N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, and its chemical structure is shown below. The erdafitinib tablet used in the disclosed intravesical system can be formulated using a salt of erdafitinib. In some specific embodiments, the erdafitinib tablet used in the disclosed intravesical system can include a lactate salt of erdafitinib. In a specific embodiment, the erdafitinib tablet used in the disclosed intravesical system can be an L-lactate salt of erdafitinib, particularly a mono-L-lactate salt of erdafitinib.

[0070]

[0071] Unless otherwise expressly stated, general references to compounds include all stereoisomers, and references to general structures or names encompass all enantiomers, diastereomers, and other optical isomers, whether in enantiomeric or racemic form, and mixtures of stereoisomers, as the context permits or requires. For any particular formula or name given, any formula or name given also includes all stereoisomers that may be produced by a particular set of substituents. Thus, for example, as used herein, reference to "lactate" encompasses both D-isomers and L-isomers.

[0072] In an embodiment, the erdafitinib pharmaceutical tablet may incorporate various excipients, including but not limited to at least one solubilizer, at least one binder, at least one wetting agent, at least one disintegrant, at least one stabilizer, at least one diluent, at least one glidant, at least one lubricant, at least one osmotic agent (zymogen), etc. or any combination thereof. In an embodiment, the erdafitinib pharmaceutical tablet may be free of various excipients or combinations of excipients, including but not limited to solubilizers, wetting agents, at least one stabilizer, at least one disintegrant, at least one osmotic agent (zymogen), or a combination thereof. In an embodiment, the erdafitinib pharmaceutical tablet comprises at least one binder, at least one filler (excipient), at least one glidant, at least one lubricant, or any combination thereof. Any excipient or any combination of excipients may be present in the intragranular composition, the extragranular composition, or both the intragranular composition and the extragranular composition. In one aspect, at least one intragranular pharmaceutical excipient and at least one extragranular pharmaceutical excipient may be the same, i.e., may be selected from at least one common (mutually present) pharmaceutical excipient. In another aspect, the intragranular pharmaceutical excipients and the extragranular pharmaceutical excipients do not include common (mutually present) pharmaceutical excipients, such that the intragranular excipients and the extragranular excipients are mutually exclusive. In an embodiment, the erdafitinib pharmaceutical tablet (particularly an erdafitinib lactate pharmaceutical tablet comprising 50 wt % to 90 wt %, 60 wt % to 80 wt %, 65 wt % to 75 wt % (e.g. 70 wt %) of the lactate form of erdafitinib (particularly its L-lactate form)) comprises at least one binder, at least one diluent, at least one glidant, at least one lubricant, or any combination thereof.

[0073] It should be understood that these functional descriptions of various excipients are generally used as follows. A solubilizer can improve or enhance the solubility of the API in the drug lumen of the disclosed system after insertion in vivo. A binder can hold the solid particles of the composition together to obtain physical stability. A wetting agent can reduce the surface tension between the drug and the medium in which it is located, and help maintain the solubility of the drug. Disintegrants can assist in the disintegration of mini tablets when contacted with water (urine) to release the drug substance. Stabilizers can improve the chemical stability of the formulation (including API), such as thermal stability, or protect the API from degradation. Diluents can be used as fillers to increase the volume or weight of the composition, which can assist in providing tablets of the desired size. Glidants can improve the flow characteristics of (granular) particles of tablet components or powder blends to be compressed. Lubricants can prevent particles of the composition from adhering to components of manufacturing equipment, such as molds and punches of tablet presses. Osmotic agents dissolve in the aqueous fluid in the delivery system and generate osmotic pressure therein.

[0074] In an embodiment, the erdafitinib L-lactate formulation may include all or only some of these excipients. For example, in one aspect, the erdafitinib L-lactate formulation may be free of solubilizers, free of wetting agents, free of disintegrants, free of stabilizers (e.g., free of meglumine), free of osmotic agents, or free of any combination of these excipients. For example, in another aspect, the drug itself, such as the lactate salt of erdafitinib, may be used as an osmotic agent. In one aspect, the drug itself, such as the lactate salt of erdafitinib, is used as an osmotic agent and the erdafitinib lactate formulation does not contain another osmotic agent. In one aspect, the excipient may be water-soluble. In another aspect, the excipient may be colloidal in water. According to another aspect, the excipient may be soluble under the conditions under which it is deployed in the patient's body (such as in the bladder). These excipients and other excipients are described in more detail below.

[0075] Stabilizers such as formaldehyde scavengers

[0076] In one aspect, when incorporated into a solid dosage form, the erdafitinib API may be susceptible to degradation under certain conditions. For example, erdafitinib may degrade or transform in the presence of formaldehyde to form a cyclized product, 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine. Formaldehyde from various sources in the environment, such as from packaging materials or as a contaminant in excipients or other components of the formulation, may come into contact with erdafitinib.

[0077] Thus, in one aspect, the Erdafitinib pharmaceutical formulation may include a formaldehyde scavenger to improve the stability or shelf life of the formulation. Various formaldehyde scavengers may be used, which can prevent, slow, reduce or delay the formation of degradation products when Erdafitinib contacts formaldehyde. Thus, the stability of the Erdafitinib pharmaceutical formulation, such as its chemical stability, may be increased in the presence of a formaldehyde scavenger compared to an Erdafitinib pharmaceutical formulation that does not contain a formaldehyde scavenger. In one aspect, the formaldehyde scavenger may be present in the solid pharmaceutical composition as a component of the intragranular solid composition, the extragranular solid composition, or both the intragranular composition and the extragranular composition. In one aspect, the formaldehyde scavenger, particularly meglumine, may be present in the solid pharmaceutical composition as a component of the intragranular solid composition.

[0078] The formaldehyde scavenger may include or may be selected from compounds containing reactive nitrogen centers, such as compounds containing amine or amide groups. Without being bound by theory, it is believed that these compounds may react with formaldehyde to form a Schiff base imine (R 1 R 2 C=NR 3 , where R 3is not hydrogen), which itself can bind formaldehyde. Examples of such formaldehyde scavengers include, but are not limited to, amino acids, amino sugars, alpha-(α-)amine compounds, their conjugates and derivatives, and mixtures thereof. Such formaldehyde scavenger compounds may contain two or more amine and / or amide moieties that can scavenge formaldehyde.

[0079] In one aspect, the formaldehyde scavenger may include or may be selected from, for example, meglumine, glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, aspartic acid, glutamic acid, arginine, lysine, ornithine, taurine, histidine, aspartame, proline, tryptophan, citrulline, pyrrolysine, asparagine, glutamine, tris(hydroxymethyl)aminomethane, their conjugates, their pharmaceutically acceptable salts, or any combination thereof. According to one aspect, the formaldehyde scavenger may include or may be selected from meglumine or a pharmaceutically acceptable salt thereof, particularly meglumine base.

[0080] Thus, one aspect of the present disclosure is the use of a formaldehyde scavenger, particularly meglumine, in an Erdafitinib pharmaceutical formulation, such as a pharmaceutical tablet formulation, to increase the stability of Erdafitinib in any form thereof, including an Erdafitinib salt form, such as Erdafitinib L-lactate. The chemical stability of the Erdafitinib pharmaceutical formulation is increased compared to an Erdafitinib pharmaceutical formulation or composition that does not contain a formaldehyde scavenger. One aspect of the present disclosure is a method of preventing, slowing, reducing or delaying the formation of degradation products, such as the following compounds, which may be formed from Erdafitinib in the presence of formaldehyde:

[0081]

[0082] In one aspect, degradation products such as the above-mentioned substances may be present in a solid tablet composition such as a minitablet formulation, particularly a minitablet as disclosed herein.

[0083] When present in the erdafitinib solid pharmaceutical composition, the formaldehyde scavenger may be present in the solid pharmaceutical composition at a concentration of 0.01 wt % to 5 wt %, 0.05 wt % to 3 wt %, 0.1 wt % to 2 wt %, 0.5 wt % to 1.5 wt %, or about 1 wt %. When present in the erdafitinib solid pharmaceutical composition, the formaldehyde scavenger may be present in the solid pharmaceutical composition at a concentration of 5 wt % to 10 wt %, about 5 wt %, about 6 wt %, about 7 wt %, about 8 wt %, about 9 wt %, or about 10 wt %.

[0084] In one aspect, the pharmaceutical composition as described herein (particularly the erdafitinib pharmaceutical tablet) does not contain a stabilizer or a formaldehyde scavenger.

[0085] Solubilizer

[0086] In one aspect, the erdafitinib formulation may include a solubilizing agent. The solubilizing agent may be an intragranular component, an extragranular component, or both an intragranular component and an extragranular component of the formulation. In an embodiment, the solubilizing agent may include or may be selected from, for example, (a) a cyclic oligosaccharide, (b) a cellulose functionalized with a methoxy, 2-hydroxypropoxy, acetyl or succinyl moiety or a combination thereof, or (c) a salt thereof. In one embodiment, the solubilizing agent is present as an intragranular component. In other aspects, the erdafitinib formulation may not contain a solubilizing agent.

[0087] In an embodiment, the solubilizer for the Erdafitinib tablet formulation may include or may be selected from oligosaccharides. In an embodiment, the solubilizer may include or may be selected from cyclic oligosaccharides such as cyclodextrins. Suitable cyclodextrin solubilizers for Erdafitinib tablet formulations include, but are not limited to, hydroxypropyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, sulfobutyl ether-β-cyclodextrin sodium salt, or any combination thereof. In other embodiments, the solubilizer may include or may be hydroxypropyl methylcellulose E5 (HPMC-E5). In other embodiments, the solubilizer for the Erdafitinib tablet formulation may include or may be hydroxypropyl methylcellulose acetate succinate.

[0088] The oligosaccharide solubilizing agent may be present in the erdafitinib tablet form at a concentration of 1% to 20%, alternatively 3% to 18%, alternatively 5% to 15%, alternatively 7% to 12%, or alternatively 10% or about 10% by weight. The cyclodextrin solubilizing agent may be present in the erdafitinib tablet formulation (e.g., erdafitinib salt formulation) at a concentration of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% by weight, or any range of weight percentages between any of these weight percentages.

[0089] In one aspect, the solubilizer used in the Erdafitinib tablet formulation disclosed herein may include or may be hydroxypropyl-β-cyclodextrin. One embodiment of the Erdafitinib formulation comprises a hydroxypropyl-β-cyclodextrin solubilizer, which may be present in the intragranular composition. In one aspect, the pharmaceutical composition as described herein (particularly the Erdafitinib pharmaceutical tablet) does not contain a solubilizer.

[0090] Adhesives

[0091] The pharmaceutical excipients for the solid pharmaceutical composition of Erdafitinib may include one or more binders. One or more binders may be present in the solid pharmaceutical composition as a component of the intragranular solid composition, the extragranular solid composition, or both the intragranular solid composition and the extragranular solid composition. Suitable binders may be water-soluble, water-insoluble or slightly water-soluble or a combination of these. In certain embodiments, binders are one aspect, and binders may include water-soluble binders, such as water-soluble polymer binders. Polymer binders may include nonionic polymers that are pH-stable in aqueous solution.

[0092] It will be appreciated by those of ordinary skill that binders can also function as diluents (also referred to as fillers) in pharmaceutical compositions. Therefore, as appropriate and unless otherwise specified, the binders provided in the present disclosure can also be used for their diluting function.

[0093] In one aspect, suitable binders may include or be selected from, but are not limited to, polyvinylpyrrolidone (PVP, also known as povidone, or poly(1-vinyl-2-pyrrolidone)), poly(vinyl acetate) (PVA), vinylpyrrolidone-vinyl acetate copolymers, polyethylene oxide (PEO, also known as poly(ethylene glycol) or PEG), polypropylene oxide (PPO, also known as poly(propylene glycol) or PPG), ethylene glycol-propylene glycol copolymers, poloxamers, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose, silicified microcrystalline cellulose, or combinations thereof. In one aspect, suitable binders may include or may be selected from polyvinyl pyrrolidone (PVP, also known as povidone or poly (1-vinyl-2-pyrrolidone)), poly (vinyl acetate) (PVA), vinyl pyrrolidone-vinyl acetate copolymer, polyethylene oxide (PEO, also known as poly (ethylene glycol) or PEG), polypropylene oxide (PPO, also known as poly (propylene glycol) or PPG), ethylene glycol-propylene glycol copolymer, poloxamer, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), or a combination thereof. In one aspect, suitable binders may include or may be selected from hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose, vinyl pyrrolidone-vinyl acetate copolymer, or a combination thereof. In one aspect, suitable binders may include or may be selected from hydroxypropyl methylcellulose (HPMC), vinyl pyrrolidone-vinyl acetate copolymer (copovidone), or a combination thereof.

[0094] In other aspects, suitable binders may include or may be selected from polymers or copolymers of vinyl pyrrolidone (VP, also known as 1-vinyl-2-pyrrolidone) and vinyl acetate (VA). Suitable binders may also include or may be selected from polymers or copolymers of ethylene oxide (EO) and propylene oxide (PO). In addition, these binders may be used in combination with other binders, such as microcrystalline cellulose, hydroxypropyl cellulose (HPC) or hydroxypropyl methylcellulose (HPMC).

[0095] In one aspect, the total concentration of at least one binder in the solid pharmaceutical composition can be 5 wt % to 30 wt %, 10 wt % to 25 wt %, 12 wt % to 22 wt %, or 14 wt % to 19 wt %. In one aspect, the total concentration of at least one binder in the solid pharmaceutical composition can be about 1 wt % to about 30 wt %, about 5 wt % to about 20 wt %, or about 10 wt % to about 15 wt %.

[0096] According to another aspect, a suitable polymer binder may include or may be selected from a copolymer of vinyl pyrrolidone and vinyl acetate, which may be referred to as poly(vinyl-pyrrolidone-co-vinyl acetate) or poly(VP-co-VA). Examples of suitable binders include VA64 and VA64 Fine (BASF, Ludwigshafen am Rhein, Germany), which have molecular weights (Mw) ranging from 45,000 g / mol to 70,000 g / mol based on light scattering measurements of the solutions. Another suitable binder is K30.

[0097] In an embodiment, a polymer binder such as a vinyl pyrrolidone-vinyl acetate copolymer may be present in the disclosed erdafitinib tablet formulation at a concentration of 2 wt % to 15 wt %, alternatively 4 wt % to 12 wt %, alternatively 6 wt % to 10 wt %, or alternatively 8 wt % or about 8 wt %. For example, the vinyl pyrrolidone-vinyl acetate copolymer binder may be present in the erdafitinib tablet formulation at a concentration of 2 wt %, 3 wt %, 4 wt %, 5 wt %, 6 wt %, 7 wt %, 8 wt %, 9 wt %, 10 wt %, 11 wt %, 12 wt %, 13 wt %, 14 wt %, 15 wt %, or any range of weight percentages between any of these weight percentages. In one aspect, the vinyl pyrrolidone-vinyl acetate copolymer is present in the intragranular composition. In one aspect, the vinyl pyrrolidone-vinyl acetate copolymer is present in the intragranular composition, and the intragranular composition is prepared by roller compaction. In one aspect, the vinyl pyrrolidone-vinyl acetate copolymer is present in the extragranular composition. In one aspect, the vinyl pyrrolidone-vinyl acetate copolymer is present in the extragranular composition at a concentration of 8 wt % to 14 wt %, or alternatively 7.5 wt % to 18.5 wt %. In one aspect, the vinyl pyrrolidone-vinyl acetate copolymer is present in the extragranular composition at a concentration of 8 wt % to 14 wt %, or alternatively 9 wt % to 13 wt %.

[0098] In one aspect, the binder may include or may be microcrystalline cellulose.For example, the microcrystalline cellulose may be present in the solid pharmaceutical composition at a concentration of 5 wt % to 20 wt %, 6 wt % to 15 wt %, or 7 wt % to 12 wt %.

[0099] According to another aspect, the binder may include or may be silicified microcrystalline cellulose.For example, the silicified microcrystalline cellulose may be present in the solid pharmaceutical composition at a concentration of 3 wt % to 18 wt %, 4 wt % to 15 wt %, or 5 wt % to 12 wt %.

[0100] According to another aspect, the binder may include or may be hydroxypropyl methylcellulose. For example, hydroxypropyl methylcellulose (e.g., HPMC 290 15 mPa.s) may be present in the solid pharmaceutical composition at a concentration of 0.5 wt % to 5 wt %, or 0.5 wt % to 2 wt %, or 1 wt % to 2 wt %.

[0101] Wetting Agents

[0102] The pharmaceutical excipients for the solid pharmaceutical composition of Erdafitinib may include one or more wetting agents. One or more wetting agents may be present in the solid pharmaceutical composition in the intragranular solid composition, the extragranular solid composition, or both the intragranular solid composition and the extragranular solid composition. In an exemplary embodiment, the wetting agent may include or may be independently selected from an anionic surfactant or a nonionic surfactant, particularly an anionic surfactant. For example, the wetting agent may include or may be independently selected from sodium lauryl sulfate, sodium stearyl fumarate, polysorbate 80, docusate sodium, or any combination thereof. In an embodiment, the total concentration of the wetting agent in the solid pharmaceutical composition may be 0.01% to 2.5% by weight, 0.05% to 1.0% by weight, or 0.1% to 0.5% by weight. In one embodiment, the wetting agent is present in the intragranular composition.

[0103] In one embodiment, the erdafitinib solid pharmaceutical composition does not comprise one or more wetting agents.

[0104] Disintegrants

[0105] The pharmaceutical excipients for the solid pharmaceutical composition of Erdafitinib may include one or more disintegrants. One or more disintegrants may be present in the solid pharmaceutical composition in the intragranular solid composition, the extragranular solid composition, or both the intragranular solid composition and the extragranular solid composition. In one embodiment, the disintegrant is present in the intragranular composition. In one embodiment, the disintegrant is present in the intragranular composition, and the intragranular composition is prepared by roller compaction.

[0106] In an exemplary embodiment, the disintegrant may include or may be independently selected from a functionalized polysaccharide or a cross-linked polymer. For example, in one aspect, the disintegrant may include or may be selected from, for example, (a) a cellulose functionalized with a methoxy, 2-hydroxypropoxy or carboxymethoxy moiety, a salt thereof, or a combination thereof, (b) a carboxymethylated starch, or (c) a cross-linked polymer.

[0107] In an embodiment, the disintegrant may include or may be independently selected from hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, crospovidone (cross-linked polyvinyl pyrrolidone), croscarmellose sodium (cross-linked sodium carboxymethyl cellulose), sodium starch glycolate, or any combination thereof.

[0108] When present, the disintegrant can be present in a range of concentrations. In embodiments, the total concentration of disintegrant in the solid pharmaceutical composition can be 0.1 wt % to 10 wt %, 0.2 wt % to 8 wt %, 0.5 wt % to 7 wt %, 1 wt % to 5 wt %, or 2 wt % to 3 wt %.

[0109] In one embodiment, the erdafitinib solid pharmaceutical composition does not comprise one or more disintegrants.

[0110] Thinner or filler

[0111] The pharmaceutical excipients for the solid pharmaceutical composition of Erdafitinib may include one or more diluents. The one or more diluents may be present in the solid pharmaceutical composition as a component of the intragranular solid composition, the extragranular solid composition, or both the intragranular solid composition and the extragranular solid composition.

[0112] In exemplary embodiments, diluent may include or may be selected from sugar, starch, microcrystalline cellulose, sugar alcohol, hydrogen phosphate, dihydrogen phosphate, carbonate or their combination. In one aspect, diluent may include or may be selected from lactose, dextrin, mannitol, sorbitol, starch, microcrystalline cellulose, silicified microcrystalline cellulose, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, calcium carbonate, sucrose or their any combination. In one aspect, diluent may include or may be selected from microcrystalline cellulose, silicified microcrystalline cellulose, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate or their any combination. In one aspect, diluent may include or may be selected from microcrystalline cellulose and silicified microcrystalline cellulose or their any combination.

[0113] In an embodiment, the total concentration of diluent in the solid pharmaceutical composition may be 10% to 30% by weight, 12% to 30% by weight, 15% to 25% by weight, or 18% to 22% by weight, or 10% to 25% by weight, or 10% to 20% by weight, or 10% to 15% by weight. In an embodiment, the total concentration of diluent in the solid pharmaceutical composition may be 5% to 30% by weight, 10% to 30% by weight, or 10% to 20% by weight. In some embodiments, the diluent includes microcrystalline cellulose, silicified microcrystalline cellulose, or a combination thereof. For example, in some aspects, the diluent may include or may be selected from a concentration of 15% to 25% by weight or 20% to 22% by weight of microcrystalline cellulose. For example, in some aspects, the diluent may include or may be selected from a concentration of 5% to 20% by weight or 7.5% to 18.5% by weight or 5% to 15% by weight or 8% to 14% by weight of microcrystalline cellulose, and / or a concentration of 5% to 10% by weight or 7% to 8% by weight of silicified microcrystalline cellulose. In some embodiments, the diluent does not include silicified microcrystalline cellulose. In another aspect, the diluent may include or may be selected from a concentration of 18% to 20% by weight of anhydrous calcium hydrogen phosphate.

[0114] It will be appreciated by those of ordinary skill that some of the diluents / fillers disclosed herein may also function as binders in pharmaceutical compositions. Thus, some compounds or materials may be described herein as providing binder functionality and providing diluent functionality.

[0115] Glidants

[0116] The pharmaceutical excipients for the solid pharmaceutical composition of Erdafitinib may include one or more glidants. One or more glidants may be present in the solid pharmaceutical composition as a component of the intragranular solid composition, the extragranular solid composition, or both the intragranular solid composition and the extragranular solid composition. In one aspect, the glidant is present in the extragranular composition. As used in the present disclosure, a glidant refers to a pharmaceutical excipient that improves or optimizes the particle flow characteristics of a granular or powdered tablet component in granular form by reducing interactions, attraction, cohesion, or friction between particles.

[0117] In one aspect, the glidant may include or may be selected from colloidal silicon dioxide, colloidal anhydrous silicon dioxide, talc or any combination thereof. In an embodiment, the total concentration of the glidant in the solid pharmaceutical composition may be 0.01% to 5% by weight, 0.05% to 3% by weight, 0.1% to 1% by weight, or about 0.2% by weight, or about 0.25% by weight, or about 0.3% by weight, about 0.35% by weight, or about 0.4% by weight, or about 0.45% by weight, or about 0.5% by weight. In an embodiment, the total concentration of the glidant in the solid pharmaceutical composition may be about 0.05% to about 1% by weight, about 0.1% to about 0.5% by weight, or about 0.25% by weight. In one embodiment, the glidant is colloidal silicon dioxide. In some embodiments, the glidant is colloidal silicon dioxide (hydrophilic). In some embodiments, the glidant is colloidal silicon dioxide (hydrophobic).

[0118] Lubricants

[0119] The pharmaceutical excipients for the solid pharmaceutical composition of Erdafitinib may include one or more lubricants. One or more lubricants may be present in the solid pharmaceutical composition as a component of the intragranular solid composition, the extragranular solid composition, or both the intragranular composition and the extragranular composition. In one aspect, the lubricant is present in the extragranular composition. In one aspect, the lubricant is present in the intragranular composition, and the intragranular composition is prepared by rolling. As used in the present disclosure, a lubricant refers to a pharmaceutical excipient added to a tablet formulation that reduces the friction of the tablet surface. In an embodiment, the lubricant may reduce the friction between the tablet surface and the processing equipment, such as the friction between the tablet surface and the wall of the mold cavity in which the tablet is formed. Therefore, when the tablet is formed and discharged, the lubricant may reduce the friction between the mold wall and the formulation particles. A pharmaceutically acceptable lubricant is a non-toxic and pharmacologically inactive substance. In addition, the lubricant may be water-soluble or water-insoluble, although they are preferably water-soluble in the drug delivery system disclosed in the present invention.

[0120] In one embodiment, the lubricant comprises or is magnesium stearate. In some embodiments, the lubricant comprises or is sodium stearyl fumarate. In some embodiments, the lubricant comprises or is polyethylene glycol (e.g., PEG8K).

[0121] In one aspect, lubricant may include or may be selected from, for example, fatty acid, fatty acid salt, fatty acid ester, talcum, glyceride, metal silicate or any combination thereof. In an embodiment, lubricant may include or may be selected from magnesium stearate, stearic acid, magnesium silicate, aluminum silicate, isopropyl myristate, sodium oleate, sodium stearoyl lactylate, sodium stearyl fumarate, titanium dioxide or a combination thereof. The example of water-soluble lubricant includes but is not limited to leucine, sodium lauryl sulfate, sucrose stearate, boric acid, sodium acetate, sodium oleate, sodium stearyl fumarate and PEG. In another aspect, the total concentration of lubricant in solid pharmaceutical composition may be 0.05% by weight to 5% by weight, 0.1% by weight to 3% by weight, 1% by weight to 2% by weight or about 1.5% by weight or about 2.5% by weight. In another aspect, the total concentration of lubricant in solid pharmaceutical composition may be 0.05% by weight to 5% by weight, 1% by weight to 5% by weight or about 2.5% by weight.

[0122] Penetrant

[0123] The drug or certain salt forms of the drug may act as an osmotic agent itself, and a pharmaceutical formulation having such a drug or its salt form may optionally include one or more additional pharmaceutically acceptable osmotic agents, which are pharmacologically inactive substances. Pharmaceutical excipients for the solid pharmaceutical composition of Erdafitinib may include one or more osmotic agents. One or more osmotic agents may be present in the solid pharmaceutical composition as a component of the intragranular solid composition, the extragranular solid composition, or both the intragranular solid composition and the extragranular solid composition. Examples of osmotic agents include, but are not limited to, inorganic salts and carbohydrates, such as urea, potassium chloride, sodium chloride, sucrose, fructose, lactose, and mannitol.

[0124] In one embodiment, the drug itself (particularly erdafitinib lactate, particularly erdafitinib mono-L-lactate) acts as a osmotic agent.

[0125] Method for preparing tablet composition

[0126] In one aspect, a method for preparing a solid pharmaceutical composition (such as a tablet, particularly a mini tablet) is provided. In some embodiments, the method includes preparing an intragranular solid composition comprising Erdafitinib L-lactate and at least one intragranular drug excipient. In some embodiments, the intragranular drug excipient includes a binder. The binder may be any binder as described herein. For example, the binder may be hydroxypropyl methylcellulose. In some embodiments, the method includes combining the intragranular solid composition with at least one extragranular drug excipient to form a blend. In some embodiments, the intragranular excipient and the extragranular excipient do not include a common excipient. In some embodiments, the extragranular excipient includes one or more of a binder, a filler, a glidant, and / or a lubricant. Each of the extragranular binders, fillers, glidants, and / or lubricants may be any binder, filler, glidant, and / or lubricant as described herein, respectively. In some embodiments, the extragranular binder includes vinyl pyrrolidone-vinyl acetate (PVP VA). In some embodiments, the extragranular filler includes microcrystalline cellulose, silicified microcrystalline cellulose, or a combination thereof. In some embodiments, the extragranular filler comprises microcrystalline cellulose. In some embodiments, the extragranular filler comprises a combination of microcrystalline cellulose and silicified microcrystalline cellulose. In some embodiments, the extragranular glidant may be any glidant as described herein. In some embodiments, the extragranular glidant comprises colloidal silicon dioxide (hydrophilic). In some embodiments, the extragranular lubricant may be any lubricant as described herein. In some embodiments, the extragranular lubricant comprises magnesium stearate. In some embodiments, the extragranular lubricant comprises sodium stearyl fumarate. In some embodiments, the extragranular lubricant comprises polyethylene glycol. In some embodiments, the method comprises tableting the blend to form a solid pharmaceutical composition. In some embodiments, tableting is characterized by an ejection force of less than about 1000N.

[0127] Osmotic drug delivery systems

[0128] Described herein are drug delivery systems that are particularly suitable for effectively releasing drug formulations containing Erdafitinib, such as those described in detail above. These particular systems utilize osmotic pressure to drive the controlled release of the drug through one or more holes in the system housing. The terms "hole" and "orifice" can be used interchangeably with "opening".

[0129] In certain embodiments, the system includes a water-permeable, drug-impermeable polymer component that forms the shell. For example, the polymer component can be formed of a biocompatible elastomeric composition having desired mechanical properties (e.g., soft, elastic flexibility), such as a silicone or thermoplastic polyurethane composition. The polymer component can have a tubular structure, such as in a double-lumen tube.

[0130] In one aspect, Figure 1A-1B As shown, the drug delivery system 100 includes a flexible device body 102 defining a drug reservoir lumen 104 and a retention frame lumen 106. The drug reservoir lumen 104 contains a plurality of solid drug tablets 108 arranged end to end in the drug reservoir lumen. In some embodiments, including as shown, the drug tablets 108 have rounded flat end faces and cylindrical side walls. The retention frame lumen 106 accommodates an elastic wire or retention frame 110. The retention frame may be a superelastic alloy, such as nitinol. A silicone spacer 120 is fixed in the end of the drug reservoir lumen 104, for example using a silicone adhesive, to close / plug the drug reservoir lumen at the end of the drug reservoir lumen 104 and retain the drug tablets 108 therein.

[0131] like Figure 1B As shown, device body 102 includes a tubular wall structure 112 defining a drug reservoir lumen 104 and a smaller tubular wall structure 114 defining a retention frame lumen 106. Wall structures 112, 114 and lumens 104, 106 are shown as being substantially cylindrical, but other variations in shape are possible.

[0132] In a preferred embodiment, the tubular wall structures 112, 114 are formed of silicone (MED-4750), and the tubular wall structure 112 has a wall thickness of 0.1 mm to 0.5 mm, or 0.15 mm to 0.4 mm, or 0.18 mm to 0.3 mm, or 0.2 mm. In some embodiments, the tubular wall structure 112 defining the drug reservoir lumen 104 may be formed of another elastomeric material that is drug-impermeable. As used herein, the term "drug-impermeable" or "drug-impermeable" refers to the shell being substantially impermeable to dissolved drug (e.g., erdafitinib) such that no significant amount of dissolved drug can diffuse through the wall during treatment when the system is located in vivo.

[0133] The device body 102 includes a hole 130 extending through the side wall of the tubular wall structure 112, which defines the drug reservoir lumen 104. In the illustrated embodiment, the device body has a single drug release hole. In an exemplary embodiment, the diameter of the hole is about 20 μm to about 500 μm, such as about 25 μm to about 300 μm, more particularly about 30 μm to about 200 μm. In one example, the hole has a diameter of about 100 μm to about 200 μm, such as about 150 μm. In some other embodiments, the device body may have two or more holes.

[0134] like Figure 2As shown, drug delivery system 100 operates as an osmotic pump in vivo. Water or urine from the patient's body diffuses through tubular wall structure 112 to contact and dissolve drug tablet 108, creating osmotic pressure to drive dissolved drug from the drug delivery system through pores (orifices) 130.

[0135] In some embodiments, the system includes a single hole, ie, a through hole, in the side wall of the tubular housing.

[0136] In some embodiments, the system is a closed structure configured to release the drug by the transient formation of microchannels defined between and at the interface of two surfaces and / or two components in the system, as described in U.S. Pat. No. 9,814,671, which is incorporated herein by reference in its entirety.

[0137] In some specific embodiments, the system includes both through-holes in the tubular housing and housing structures that are configured to release the drug by the transient formation of microchannels defined between and at the interface of two surfaces and / or two components, as described in U.S. Pat. No. 11,020,575, which is incorporated herein by reference in its entirety. In some embodiments, the microchannels are formed in response to hydrostatic pressure that accumulates in the water-permeable body due to osmotic influx of water. When the hydrostatic pressure increases above a certain threshold, the microchannels form, thereby forcing at least a portion of the drug to leave the device and relieve the hydrostatic pressure buildup in the drug reservoir. When the hydrostatic pressure has been released, the microchannels may at least partially collapse. The process repeats itself until all or a majority of the drug has been released, or the osmotic influx of water is insufficient to continue the process. As Fig.16A and Fig. 16CAs shown, the drug delivery device 50 includes a device body 52 having a water-permeable wall portion 64 that defines a reservoir 60 (also referred to herein as a "reservoir lumen" or "drug reservoir lumen") that contains a payload 58, such as a drug formulation (e.g., a microtablet). The water-permeable wall portion 64 can generally be configured to allow water to enter the device and contact the drug formulation (i.e., payload) 58 located in the reservoir 60 to promote the release of the fluidized drug 58A from the device. For example, osmotic flow of water into the reservoir 60 can generate pressure within the reservoir 60, which drives the release of the fluidized drug 58A from the reservoir 60 via one or more mechanisms. For example, in the embodiments described herein, the release of the fluidized drug 58A from the device can occur through one or more preformed sidewall orifices 66 and / or through the transient formation of one or more microchannels 62 that lead to an opening in the end of the device. For example, the device 50 may also include an elastic portion 54 that surrounds the constraining plug 56 and controls the release of the drug from the device by transiently forming one or more microchannels 62 between 54 and 56. As shown by the dashed arrows, water diffuses through the water-permeable wall 64 of the body 52 and enters the drug reservoir 60 to form a fluidized drug 58A, which may be, for example, an aqueous solution containing the drug provided in the payload 58 initially loaded into the reservoir 60. The hydrostatic pressure in the reservoir 60 causes the fluidized drug 58A to be pushed out of the reservoir 60 between the elastic portion and the constraining plug through the microchannels 62 formed between the elastic portion 54 and the constraining plug 56, for example, by elastic deformation of one or both interfacial surfaces. In certain embodiments described herein, a combination of these release mechanisms is employed to provide a desired drug release profile.

[0138] like Fig. 16B As shown, Fig.16A The device 50 is shown in a plan view in a relatively expanded shape suitable for being maintained in the body, such as in a bladder. The device includes a water-permeable body 52 having a drug reservoir portion 78 and a retaining frame portion 76. The retaining frame portion 76 may include a retaining frame 74 that is capable of deforming between a relatively expanded shape suitable for insertion into the bladder via a catheter and a relatively low-profile shape. In some embodiments, the retaining frame 74 includes or is composed of an elastic wire. For example, the retaining frame 74 is an elastic wire formed from a superelastic alloy (such as nitinol). The drug reservoir lumen may be loaded with a plurality of drug units 158 arranged in series. The drug unit may be a tablet, such as a microtablet. As used herein, the term "drug reservoir portion" refers to the portion of the device that forms and defines a "drug reservoir" or "drug reservoir lumen". For the purposes of this disclosure, the term "retention shape" generally refers to any shape suitable for retaining the device in the bladder, including but not limited to, Fig. 16BCurled or "pretzel" shape as shown. The retention shape allows the device to be discharged without being entrained in urine when the patient urinates. The terms "relatively expanded shape", "relatively high profile shape" and "retention shape" are used interchangeably.

[0139] Reference again Figure 2 , the device body 102 can be formed by a molding or extrusion process or an additive manufacturing process. In some embodiments, where the drug component and the device component are prepared separately and then combined, the drug component (e.g., a tablet) is loaded into the drug reservoir lumen, and the drug reservoir lumen is then closed at its ends, for example, with a silicone spacer and / or an adhesive. In some other embodiments, the drug component and the device component are produced together, such as in an additive manufacturing process, such as a 3D printing process known in the art.

[0140] In embodiments, system is configured for intravesical insertion and remains in patient's body.In preferred embodiments, this system can be elastically deformed between the low profile deployment shape (for example, relatively straight shape) that is suitable for inserting through patient's urethra and entering patient's bladder and the relatively expanded retention shape (for example, kraft paper shape, double oval curled shape, S shape etc.) that is suitable for remaining in bladder.For example, the shell or the tube of system can have two relative free ends, and these two relative free ends are guided away from each other when system is in the low profile deployment shape and are guided towards each other when system is in the relatively expanded retention shape.The relatively expanded shape can comprise a pair of overlapping curling, sometimes referred to as "kraft paper " shape.In specific embodiments, the end of elongated system is usually located in the boundary of the retention shape that double oval sample expands.

[0141] In the bladder, the system should be compliant (i.e., bend easily, feel soft) during detrusor contraction to avoid or reduce discomfort and irritation to the patient. For example, the system can be configured for tolerance based on the bladder characteristics and design considerations described in U.S. Pat. No. 11,065,426, which is incorporated herein by reference.

[0142] In some embodiments, the system includes a retention frame lumen, and in some embodiments of these embodiments, the retention frame lumen includes a retention frame, i.e., an elastic wire, such as a nitinol wire. In certain other embodiments, the retention frame lumen is filled with a shaped elastic polymer. In certain other embodiments, the system does not include a retention frame lumen or a retention frame or wire. On the contrary, the material of the shell is configured to be able to elastically deform between a straightened shape and a retention shape in the absence of a retention frame or wire. For example, in certain embodiments, the tubular shell is heat-set to have a curled shape or other retention shape.

[0143] In an embodiment, the tubular housing may be formed of a water-permeable material. In a preferred embodiment, as described above for the erdafitinib solid formulation, the drug is in solid form (e.g., one tablet or multiple tablets), and the tubular body is water-permeable to allow the drug to dissolve in vivo when in the lumen of the drug reservoir. In some other embodiments, the solid formulation may be in the form of flowable particles, such as beads, granules, powders, etc.

[0144] In some embodiments, the material used for the wall structure of the system of the present invention is selected from silicone and suitable thermoplastic polyurethane (TPU) based materials known in the art. In some embodiments, the material used for the wall structure is a platinum cured silicone elastomer.

[0145] In one aspect, the system housing is in the form of an annulus, i.e., a cylindrical tube. In one embodiment, the inner diameter of the cylindrical tube may be 1.0 mm to 3.0 mm, or 2.0 mm to 3.0 mm, or 2.2 mm to 2.8 mm, or 2.6 mm to 2.7 mm, or 2.64 mm. In one embodiment, the outer diameter of the cylindrical tube is about 2.0 mm to about 4.1 mm. In one embodiment, the thickness of the wall structure (annulus) of the cylindrical tube is about 0.2 mm to about 1.0 mm.

[0146] In embodiments, system as described herein is configured to release the medicine of therapeutically effective amount, wherein the release rate of the medicine from the drug delivery system is zero order in at least 36 hours. In one embodiment, the release rate of the medicine from the drug delivery system is substantially zero order in at least 7 days. In embodiments, system is configured to release the medicine of therapeutically effective amount in the time period of 2 days to 6 months (for example, 2 days to 90 days, 7 days to 30 days or 7 days to 14 days). Ideally, the release rate of the medicine from the drug delivery system is zero order in at least 7 days (for example, 7 to 14 days) or longer time (such as up to 3 months or 90 days). In certain embodiments, system is configured to start releasing the medicine after the lag time.

[0147] In some embodiments, the system is configured to release Erdafitinib at an average rate of 1 mg / day to 10 mg / day according to the desired treatment regimen. In some embodiments, the system is configured to release Erdafitinib at an average rate of 1 mg / day to 2 mg / day. In some embodiments, the system is configured to release Erdafitinib at an average rate of 4 mg / day to 6 mg / day. In some embodiments, the system is configured to release Erdafitinib at an average rate of 2 mg / day or 4 mg / day. In some embodiments, the system is configured to release Erdafitinib with a zero-order release profile.

[0148] The osmotic drug delivery system may be loaded with a solid form of erdafitinib salt, such as a tablet described throughout the disclosure. For example, the system may have a drug reservoir lumen configured to accommodate several disclosed drug tablets arranged end-to-end in a slender form. In some embodiments, the system accommodates about 10 to 100 cylindrical drug tablets (e.g., 44 tablets), such as mini tablets, which can be continuously loaded in the drug reservoir lumen. In some embodiments, the system accommodates about 10 to 100 cylindrical drug tablets (e.g., about 40 to 50 tablets), such as mini tablets, which can be continuously loaded in the drug reservoir lumen. In some embodiments, each mini tablet has a mass of about 20 mg to about 30 mg, or about 22 mg to about 24 mg. In some embodiments, the formulation comprises a mini tablet having a total length of about 14 cm to about 16 cm, about 14.5 cm to about 15.5 cm, or about 14.7 cm to about 14.8 cm. In some embodiments, the total tablet mass loaded into the system is about 900 mg to about 1000 mg. In some embodiments, the total tablet mass loaded into the system is about 920 mg to about 965 mg. In some embodiments, the total tablet mass loaded into the system is about 920 mg to about 950 mg. In some embodiments, the system comprises about 500 mg to about 750 mg of erdafitinib (free base equivalent).

[0149] In some embodiments, the drug delivery system includes: a dual-lumen system comprising a silicone tube having a wall thickness of 0.2 mm, wherein the dual-lumen system includes (i) a retention frame lumen ("small lumen") having a closed wireform as a retention feature, and (ii) a drug reservoir lumen ("large lumen") having an inner diameter of 2.64 mm filled with a plurality of microtablets, wherein the silicone tube surrounding the drug reservoir lumen includes a single 150 μm orifice, and wherein the drug reservoir lumen is sealed by two end plugs (e.g., polyparaxylene-coated end plugs) that are sealed to the silicone tube surrounding the drug reservoir lumen (e.g., using a silicone adhesive) and are capable of forming a transient microchannel. A plurality of minitablets can have, for example, a total minitablet length of about 15.0 cm and a total tablet mass of about 932 mg (e.g., 620 mg of erdafitinib (free base equivalent) when the minitablets contain 80 wt % erdafitinib mono-L-lactate, 18 wt % microcrystalline cellulose, 0.5 wt % hydrophilic colloidal silicon dioxide, and 1.5 wt % magnesium stearate). A plurality of mini-tablets may have, for example, a total mini-tablet length of about 15.0 cm and a total tablet mass of about 932 mg (e.g., 620 mg of erdafitinib (free base equivalent) when the mini-tablets comprise 80 wt % erdafitinib mono-L-lactate, intragranular; 18 wt % microcrystalline cellulose, intragranular; 0.5 wt % hydrophilic colloidal silicon dioxide, such as 0.3 wt % intragranular plus 0.2 wt % extragranular; 1.5 wt % magnesium stearate, such as 0.75 wt % intragranular and 0.75 wt % extragranular). In some embodiments, the drug delivery system exists in two shapes, one having a wire structure of a low profile (e.g., straightened) deployment shape, and the other having a relatively extended (e.g., German lye bread) retention shape. In some embodiments, the drug delivery system is prototype 4.

[0150] In some embodiments, the drug delivery system includes: a dual-lumen system comprising a silicone tube having a wall thickness of 0.2 mm, wherein the dual-lumen system includes (i) a retaining frame lumen ("small lumen") with a closed wire structure as a retaining feature, and (ii) a drug reservoir lumen ("large lumen") having an inner diameter of 2.64 mm filled with a plurality of microtablets, wherein the silicone tube surrounding the drug reservoir lumen includes a single 150 μm orifice, and wherein the drug reservoir lumen is sealed by two end plugs (e.g., polyparaxylene-coated end plugs) that are sealed to the silicone tube surrounding the drug reservoir lumen (e.g., using a silicone adhesive) and are capable of forming a transient microchannel. The plurality of mini-tablets may have, for example, a total mini-tablet length of about 15.0 cm and a total tablet mass of about 961 mg (e.g., 726 mg of erdafitinib (free base equivalent) when the mini-tablets comprise 90.8 wt % erdafitinib mono-L-lactate, 4.5 wt % polyethylene glycol (e.g., PEG8K), and 4.7 wt % polyvinyl pyrrolidone). The plurality of mini-tablets may have, for example, a total mini-tablet length of about 15.0 cm and a total tablet mass of about 961 mg (e.g., 726 mg of erdafitinib (free base equivalent) when the mini-tablets comprise 90.8 wt % erdafitinib mono-L-lactate, intragranular; 4.5 wt % polyethylene glycol (e.g., PEG8K), extragranular; 4.7 wt % polyvinyl pyrrolidone, intragranular). In some embodiments, the drug delivery system exists in two shapes, one having a low profile (eg, straightened) deployed shape of the wire structure, and the other having a relatively expanded (eg, kraut) retention shape. In some embodiments, the drug delivery system is Prototype 5.

[0151] The present disclosure also includes variations of Prototype 4 and Prototype 5, wherein the mini-tablets may include any pharmaceutical formulation as described herein. In some embodiments, Prototype 4 includes a mini-tablet containing 20% ​​by weight of a water-insoluble excipient. In some embodiments, Prototype 5 includes a mini-tablet containing only a water-soluble excipient. In some embodiments, Prototype 4 or Prototype 5 may include any pharmaceutical formulation as described herein, including Concept 1, Concept 2, Concept 3, Concept 4, or Concept 5.

[0152] As discussed herein with respect to the erdafitinib drug formulation, the drug can be provided in a solid form suitable for loading into the drug reservoir lumen of the system. In some embodiments, the individual drug tablets can have substantially any selected shape and size suitable for use within the system described herein. In one embodiment, the size and shape of the drug unit are set so that the drug reservoir lumen in the housing is substantially filled with a selected number of drug tablets. Each tablet has a cross-sectional shape that substantially corresponds to the cross-sectional shape of the drug reservoir lumen of a particular housing. For example, the tablet can be substantially cylindrical in shape for positioning in a substantially cylindrical drug reservoir lumen.

[0153] In one embodiment, the drug unit (tablet) is shaped to be arranged in a row when the system is in its deployment configuration. For example, the cross-sectional shape that each drug unit has can correspond to the cross-sectional shape of the drug reservoir lumen in the shell, and the end face shape that each drug unit has can correspond to the end face of adjacent drug units. The gap or fracture between the drug units can adapt to the deformation or movement of the system such as during deployment, while allowing each drug unit to keep its solid form. Therefore, although the drug delivery system is loaded with solid drugs, it can still be relatively flexible or deformable, because each drug unit can be allowed to move relative to adjacent drug units.

[0154] In an embodiment, the drug unit is a "mini tablet" whose size and shape are suitable for insertion through the natural lumen of the body (such as the urethra). For the purposes of this disclosure, the term "mini tablet" generally refers to a solid drug unit that is substantially cylindrical in shape, having an end face and a substantially cylindrical side. The diameter of the mini tablet extending along the end face is in the range of about 1.0 mm to about 3.2 mm, such as between about 1.5 mm and about 3.1 mm. The length of the mini tablet extending along the side is in the range of about 1.7 mm to about 4.8 mm, such as between about 2.0 mm and about 4.5 mm. The friability of the tablet can be less than about 2%.

[0155] Methods of drug delivery and treatment

[0156] The systems and methods disclosed herein may be suitable for use in humans or in veterinary or livestock applications. Thus, the term "patient" may refer to a human or other mammalian subject. In one embodiment, the patient is a human subject. The patient may be a cancer patient.

[0157] In certain embodiments, provided herein is a method for treating urothelial carcinoma (such as bladder cancer). In certain embodiments, provided herein is the use of a drug delivery system as described herein in the manufacture of a drug for treating urothelial carcinoma (such as bladder cancer). In certain embodiments, provided herein is a drug delivery system as described herein used in treating urothelial carcinoma (such as bladder cancer). In certain embodiments, provided herein is erdatinib used in a drug delivery system as described herein for treating urothelial carcinoma (such as bladder cancer). The method or use may include locally delivering or administering erdatinib (such as in any formulation described herein) to the bladder of a patient (particularly a cancer patient) in need of treatment in an amount (e.g., as described herein, about 1 mg / day to 10 mg / day) effective for treating bladder cancer. For example, the treatment can effectively treat muscle invasive bladder cancer (MIBC), non-muscle invasive bladder cancer (NMIBC) and / or bladder cancer not undergoing bacillus Calmette-Guerin (BCG). In one aspect, a patient (particularly a human being) is a bladder cancer or NMIBC or MIBC cancer patient experiencing BCG. In one aspect, the patient (particularly the human being) is a bladder cancer or NMIBC or MIBC cancer patient who has not undergone BCG. In one aspect, the patient (particularly the human being) is a high-risk papillary NMIBC (high-grade Ta / T1) cancer patient who has undergone recurrent BCG (BCG), and refuses or is not eligible to undergo radical cystectomy (RCy). In one aspect, the patient (particularly the human being) is a high-risk papillary NMIBC (high-grade Ta / T1) cancer patient who has undergone recurrent BCG, and plans to undergo RCy. In one aspect, the patient (particularly the human being) is a recurrent, medium-risk NMIBC (Ta and T1) cancer patient who has only a history of low-grade disease. In one aspect, the patient (particularly the human being) is a MIBC cancer patient who plans to undergo RCy, and has refused or is not eligible to undergo neoadjuvant chemotherapy based on cisplatin.

[0158] In certain embodiments, a urothelial cancer as described herein is susceptible to a FGFR2 genetic alteration and / or a FGFR3 genetic alteration.

[0159] As used herein, "FGFR genetic alteration" refers to the change of wild-type FGFR gene, including but not limited to FGFR fusion gene, FGFR mutation, FGFR amplification or any combination thereof, particularly FGFR fusion gene, FGFR mutation or any combination thereof. In certain embodiments, FGFR2 or FGFR3 genetic alteration is FGFR gene fusion. "FGFR fusion" or "FGFR gene fusion" refers to a gene encoding a part of FGFR (e.g., FGRF2 or FGFR3) and one or a part thereof in the fusion partner disclosed herein, which is produced by a translocation between two genes. The terms "fusion" and "translocation" are used interchangeably herein. The presence of one or more of the following FGFR fusion genes in a biological sample from a patient can be determined using the disclosed method or uses or by methods known to those of ordinary skill in the art: FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BICC1, FGFR2-CASP7 or any combination thereof. In certain embodiments, FGFR3-TACC3 is FGFR3-TACC3 variant 1 (FGFR3-TACC3 V1) or FGFR3-TACC3 variant 3 (FGFR3-TACC3 V3). Table A provides FGFR fusion genes and fused FGFR and fusion partner exons. The sequences of each FGFR fusion gene are disclosed in Table A2. The underlined sequences correspond to FGFR3 or FGFR2, and the other sequences represent fusion partners.

[0160] Table A

[0161] Fusion gene FGFR exons Partner exon FGFR2 FGFR2-BICC1 19 3 FGFR2-CASP7 19 4 FGFR3 FGFR3-BAIAP2L1 18 2 FGFR3-TACC3 V1 18 11 FGFR3-TACC3 V3 18 10

[0162] Table A2

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172] FGFR genetic changes include FGFR single nucleotide polymorphisms (SNPs). "FGFR single nucleotide polymorphisms" (SNPs) refer to FGFR2 or FGFR3 genes, wherein a single nucleotide is different between individuals. In certain embodiments, FGFR2 or FGFR3 genetic changes are FGFR3 gene mutations. In particular, "FGFR single nucleotide polymorphisms" (SNPs) refer to FGFR3 genes, wherein a single nucleotide is different between individuals. The presence of one or more of the following FGFR SNPs from the biological sample of the patient can be determined by methods known to those of ordinary skill in the art or methods disclosed in WO 2016 / 048833, FGFR3 R248C, FGFR3 S249C, FGFR3G370C, FGFR3 Y373C or any combination thereof. The sequence of FGFR SNPs is provided in Table B.

[0173] Table B

[0174]

[0175]

[0176] The sequence corresponds to nucleotides 920-1510 of FGFR3 (Genebank ID# NM_000142.4).

[0177] Bold underlined nucleotides indicate SNPs.

[0178] *Sometimes incorrectly referred to as Y375C in the literature.

[0179] In certain embodiments, the method or purposes for treating urothelial carcinoma as described herein include the following, consist of the following or consist essentially of the following: apply a drug delivery system as described herein to a patient, the patient has been diagnosed with urothelial carcinoma as described herein and has at least one FGFR2 genetic change and / or FGFR3 genetic change (that is, one or more FGFR2 genetic changes, one or more FGFR3 genetic changes or their combination). In certain embodiments, the FGFR2 genetic change and / or FGFR3 genetic change are FGFR3 gene mutations, FGFR2 gene fusions or FGFR3 gene fusions. In some embodiments, FGFR3 gene mutations are R248C, S249C, G370C, Y373C or any combination thereof. In still another embodiment, the FGFR2 or FGFR3 gene fusions are FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BICC1, FGFR2-CASP7 or any combination thereof.

[0180] Also described herein are methods or uses for treating urothelial carcinoma as described herein, which methods or uses comprise, consist of, or consist essentially of: (a) assessing the presence of one or more FGFR gene alterations (particularly one or more FGFR2 or FGFR3 gene alterations) in a biological sample from a patient with urothelial carcinoma as described herein; and (b) if one or more FGFR gene alterations (particularly one or more FGFR2 or FGFR3 gene alterations) are present in the sample, administering a drug delivery system as described herein to the patient.

[0181] The following methods for assessing the presence or absence of one or more FGFR genetic alterations in a biological sample are equally applicable to any of the above disclosed methods of treatment and uses.

[0182] Suitable methods for assessing the presence of one or more FGFR genetic changes in a biological sample are described herein and in WO 2016 / 048833 and U.S. Patent Application Serial No. 16 / 723,975 (which are incorporated herein in their entirety). For example, and not intended to be limiting, assessing the presence of one or more FGFR genetic changes in a biological sample may include any combination of the following steps: isolating RNA from a biological sample; synthesizing cDNA from RNA; and amplifying cDNA (pre-amplification or non-pre-amplification). In some embodiments, assessing the presence of one or more FGFR genetic changes in a biological sample may include: amplifying cDNA from a patient with a pair of primers that bind and amplify one or more FGFR genetic changes; and determining whether there are one or more FGFR genetic changes in the sample. In some aspects, cDNA may be pre-amplified. In some aspects, the assessment step may include isolating RNA from a sample, synthesizing cDNA from the isolated RNA, and pre-amplifying cDNA.

[0183] Suitable primer pairs for performing the amplification step include, but are not limited to, those disclosed in WO 2016 / 048833, as exemplified in Table C below:

[0184] Table C

[0185]

[0186]

[0187] The presence of one or more FGFR genetic alterations can be assessed at any suitable time point, including at diagnosis, after tumor resection, after first-line treatment, during clinical treatment, or any combination thereof.

[0188] The methods and uses may further comprise assessing the presence of one or more FGFR genetic alterations in the biological sample prior to the administering step.

[0189] Diagnostic testing and screening are usually performed on a biological sample selected from blood, lymph, bone marrow, solid tumor samples or any combination thereof. In certain embodiments, the biological sample is a solid tumor sample. In certain embodiments, the biological sample is a blood sample.

[0190] Methods for identifying and analyzing genetic alterations and protein upregulation are known to those skilled in the art.Screening methods may include, but are not limited to, standard methods such as reverse transcriptase polymerase chain reaction (RT PCR) or in situ hybridization such as fluorescence in situ hybridization (FISH).

[0191] Identification of an individual carrying a genetic alteration in FGFR, particularly an FGFR genetic alteration as described herein, may mean that the patient will be particularly suitable for treatment with erdafitinib. Tumors may be preferentially screened for the presence of FGFR variants prior to treatment. The screening process typically involves direct sequencing, oligonucleotide microarray analysis, or mutant-specific antibodies. In addition, diagnosis of tumors with such genetic alterations may be performed using techniques known to those skilled in the art and as described herein, such as RT-PCR and FISH.

[0192] In addition, for example, genetic changes in FGFR can be identified by direct sequencing of tumor biopsies, for example, using PCR, and methods for directly sequencing PCR products as described above. The skilled person will recognize that all such well-known techniques for detecting overexpression, activation or mutation of the above-mentioned proteins are applicable to the present case.

[0193] In screening by RT-PCR, by producing a cDNA copy of mRNA, the level of mRNA in the tumor is assessed by amplifying the cDNA by PCR. The method of PCR amplification, the selection of primers and the conditions of amplification are known to those skilled in the art. Nucleic acid manipulation and PCR are performed by standard methods, such as Ausubel, FM et al., (2004) Current Protocols in Molecular Biology, John Wiley & Sons Inc., or Innis, MA et al., (1990) PCR Protocols: a guide to methods and applications, Academic Press, San Diego. Reactions and operations involving nucleic acid technology are also described in Sambrook et al., (2001), 3rd edition, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press. Alternatively, commercially available kits for RT-PCR (e.g., Roche Molecular Biochemicals) can be used, or methods as described in U.S. Patents 4,666,828; 4,683,202; 4,801,531; 5,192,659, 5,272,057, 5,882,864, and 6,218,529, and incorporated herein by reference. An example of an in situ hybridization technique for assessing mRNA expression is fluorescence in situ hybridization (FISH) (see Angerer (1987) Meth. Enzymol., 152:649).

[0194] Typically, in situ hybridization includes the following major steps: (1) fixing the tissue to be analyzed; (2) subjecting the sample to a pre-hybridization treatment to increase accessibility of the target nucleic acid and reduce non-specific binding; (3) hybridizing the nucleic acid mixture to the nucleic acid in the biological structure or tissue; (4) washing after hybridization to remove unbound nucleic acid fragments during hybridization, and (5) detecting the hybridized nucleic acid fragments. Probes for such applications are typically labeled, for example, with radioisotopes or fluorescent reporters. Preferred probes are sufficiently long, for example, from about 50, 100, or 200 nucleotides to about 1000 or more nucleotides, to be able to specifically hybridize to the target nucleic acid under stringent conditions. Standard methods for performing FISH are described in Ausubel, FM et al., eds., (2004) Current Protocols in Molecular Biology, John Wiley & Sons Inc and Fluorescence In Situ Hybridization: Technical Overview, John MS, Bartlett in Molecular Diagnosis of Cancer, Methods and Protocols, 2nd ed.; ISBN: 1-59259-760-2; March 2004, pp. 077-088; Series: Methods in Molecular Medicine.

[0195] The method of gene expression profiling is described by (DePrimo et al., (2003), BMC Cancer, 3:3). Briefly, the protocol is as follows: double-stranded cDNA is synthesized from total RNA using a (dT)24 oligomer (SEQ ID NO:38: tttttttttt ttttttttttt tttt), first priming the first-strand cDNA synthesis, followed by second-strand cDNA synthesis using random hexamer primers. The double-stranded cDNA is used as a template for in vitro transcription of cRNA using biotinylated ribonucleotides. The cRNA is chemically fragmented according to the protocol described by Affymetrix (Santa Clara, CA, USA), and then hybridized overnight on a human genome array.

[0196] Alternatively, the protein product expressed by mRNA can be measured by immunohistochemistry of tumor samples, solid phase immunoassay with microtiter plates, Western blot, 2-dimensional SDS-polyacrylamide gel electrophoresis, ELISA, flow cytometry and other methods known in the art for detecting specific proteins. Detection methods include the use of site-specific antibodies. The technician will recognize that all such well-known techniques for detecting FGFR upregulation or detecting FGFR variants or mutants are applicable to the present situation.

[0197] Abnormal levels of proteins such as FGFR can be measured using standard enzyme assays such as those described herein. Activation or overexpression in tissue samples (e.g., tumor tissue) can also be detected by measuring tyrosine kinase activity with an assay such as that from Chemicon International. The tyrosine kinase of interest is immunoprecipitated from a sample lysate and its activity is measured.

[0198] Alternative methods for measuring overexpression or activation of FGFR (including its subtypes) include measuring microvessel density. This can be measured, for example, using the method described by Orre and Rogers (Int J Cancer (1999), 84 (2) 101-8). Determination methods also include the use of markers.

[0199] Therefore, all of these techniques can also be used to identify tumors that are particularly suitable for treatment with the drug delivery system of the present invention.

[0200] According to certain embodiments, commercially available kits (including, but not limited to, QIAGEN FGFR RGQ RT-PCR Kit) to identify FGFR2 and / or FGFR3 genetic alterations.

[0201] In certain embodiments, the method of administering a drug to a patient comprises inserting a drug delivery system as described herein into the patient and allowing the drug to be released from the system. For example, the system may include any feature or combination of features described herein. In certain embodiments, the release profile of the drug is substantially independent of pH in the pH range of 5 to 7.

[0202] In some embodiments, allowing the drug to be released from the system includes allowing water to be absorbed through the permeable wall defining the lumen of the drug reservoir to contact and dissolve the drug formulation and generate osmotic pressure in the lumen of the drug reservoir; then allowing the dissolved drug to be released from the system through the pores in the system driven by the osmotic pressure. That is, in some embodiments, the elution of the drug from the system occurs after the drug is dissolved in the system. Body fluid (e.g., urine) enters the system, contacts and dissolves the drug, and then the dissolved drug is pumped out of the system through one or more pores in fluid communication with the lumen of the drug reservoir by osmotic pumping.

[0203] In certain embodiments, the insertion includes deploying the system through the patient's urethra and entering the patient's bladder. The system can release the drug for several days, weeks, months or longer after the insertion procedure ends. In one embodiment, the deployment of the drug delivery system in the patient includes inserting the system into the patient's body cavity or lumen via a deployment device. For example, the system can be deployed by a deployment device (such as a catheter or cystoscope) positioned in the natural lumen of the body (such as the urethra), or deployed in a body cavity (such as the bladder). The deployment device is usually removed from the body cavity, and the drug delivery system is maintained in the bladder or other body cavities for a continuous prescribed treatment period.

[0204] In one example, the system is deployed by passing the drug delivery system through a deployment device and releasing the system from the deployment device into the bladder. In an embodiment, once the system emerges from the deployment device into the bladder, the system presents a retaining shape, such as an expanded or higher profile shape. The deployment device can be a commercially available system or a system particularly suitable for the drug delivery system of the present invention. In one embodiment, the deployment of the drug delivery system in the patient includes (i) elastically deforming the system into a relatively straight shape; (ii) inserting the system through the lumen of the insertion catheter (e.g., driven by a stylet) through the patient's urethra; and (iii) releasing the system from the insertion catheter into the patient's bladder so that it presents a curled retaining shape.

[0205] Once deployed in vivo, the system then releases a drug (e.g., erdafitinib) locally to the tissue at the deployment site for treating one or more conditions or diseases. The release is controlled to release an effective amount of the drug over an extended period of time. In certain embodiments, the system is present in the bladder and releases the drug over a predetermined period of time (such as two weeks, three weeks, four weeks, six weeks, two months, three months, or longer).

[0206] The system of deployment releases the medicine of desired amount in the expected predetermined time period.In embodiments, system can deliver the medicine of desired dosage in the extended time period, such as 2 days to 90 days (for example, 3 days, 5 days, 7 days, 10 days, 14 days, 20 days, 21 days, 25 days, 28 days, 30 days, 40 days, 45 days, 50 days, 60 days, 70 days, 80 days or 90 days), 1 month to 6 months (for example, 6 weeks, 1 month, 2 months, 3 months, 4 months or 5 months) or longer time.Can select the delivery rate and dosage of medicine according to the medicine delivered and the disease or illness treated.In one embodiment, the release rate of medicine from drug delivery system is zero order in at least 36 hours.In one embodiment, the release rate of medicine from drug delivery system is zero order substantially in at least 7 days, two weeks, three weeks, four weeks, one month, two months, three months or longer time.

[0207] The system can then be retrieved from the bladder through the urethra using a cystoscope or catheter. If necessary, the system loaded with new medication can then be inserted during the same procedure as retrieval or later.

[0208] The present disclosure may be further understood by reference to the following non-limiting examples.

[0209] Enumeration implementation

[0210] 1. A drug delivery system comprising:

[0211] an elongated body configured for intravesical insertion into a patient; and

[0212] a pharmaceutical preparation located within the elongated body, the pharmaceutical preparation comprising erdafitinib (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine) or a pharmaceutically acceptable salt thereof,

[0213] The drug delivery system is configured to release the erdafitinib from one or more openings in the elongated body.

[0214] 2. The drug delivery system according to embodiment 1, wherein the drug formulation comprises a salt form of erdafitinib.

[0215] 3. The drug delivery system according to embodiment 2, wherein the salt form comprises L-lactate of erdafitinib.

[0216] 4. The drug delivery system according to embodiment 1, wherein erdafitinib is in the form of a mono-L-lactate salt.

[0217] 5. The drug delivery system of any one of embodiments 1 to 4, wherein the elongated body comprises a biocompatible elastomer.

[0218] 6. A drug delivery system according to embodiment 5, wherein the biocompatible elastomer comprises silicone or thermoplastic polyurethane.

[0219] 7. A drug delivery system according to any one of embodiments 1 to 6, wherein at least one of the one or more openings in the slender body is located in a side wall of the slender body.

[0220] 8. A drug delivery system according to any one of embodiments 1 to 7, wherein at least one of the one or more openings in the slender body is located at a first end and / or an opposite second end of the slender body.

[0221] 9. A drug delivery system according to any one of embodiments 1 to 6, having a single opening, wherein the single opening is located at a position between the first end and the opposite second end of the slender body in the side wall of the slender body.

[0222] 10. The drug delivery system according to any one of embodiments 1 to 9, wherein the drug formulation comprises at least one pharmaceutical excipient.

[0223] 11. A drug delivery system according to embodiment 10, wherein the at least one drug excipient includes or is selected from a solubilizer, a binder, a diluent (filler), a wetting agent, a disintegrant, a glidant, a lubricant, a formaldehyde scavenger, an osmotic agent or any combination thereof.

[0224] 12. A drug delivery system according to embodiment 10, wherein the at least one drug excipient includes or is selected from a binder, a diluent (filler), a glidant, a lubricant or any combination thereof.

[0225] 13. The drug delivery system according to any one of embodiments 1 to 12, wherein the erdafitinib is present in the drug formulation at a concentration of 60 wt% to 80 wt%.

[0226] 14. The drug delivery system according to embodiment 13, wherein the erdafitinib is present in the drug formulation at a concentration of 70% by weight.

[0227] 15. The drug delivery system according to any one of embodiments 1 to 14, wherein the drug formulation is in the form of a plurality of mini-tablets.

[0228] 16. The drug delivery system according to any one of embodiments 1 to 15, wherein the drug delivery system is configured to release the erdafitinib through one or more openings in the elongated body by osmotic pressure.

[0229] 17. A drug delivery system according to any one of embodiments 1 to 16, wherein the slender body includes an annular wall structure defining a drug reservoir lumen, and the drug formulation is disposed in the drug reservoir lumen.

[0230] 18. A drug delivery system according to embodiment 17, wherein the one or more openings in the slender body include a single hole in the annular wall structure, and the slender body is constructed to release the erdafitinib through the hole and / or through microchannels transiently formed at one or both end regions of the annular wall structure.

[0231] 19. An intravesical drug delivery system comprising:

[0232] an elongated body configured for intravesical insertion into a patient; and

[0233] a drug formulation disposed in the elongated body, the drug formulation comprising an L-lactate salt of erdafitinib (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine),

[0234] The drug delivery system is configured to release the erdafitinib from the one or more openings in the elongated body driven by osmotic pressure.

[0235] 20. The system according to any one of embodiments 1 to 19, wherein the system is configured to release the erdafitinib at an average rate of 1 mg / day to 10 mg / day.

[0236] 21. The system according to any one of embodiments 1 to 19, wherein the system is configured to release the erdafitinib at an average rate of 1 mg / day to 6 mg / day.

[0237] 22. The system according to any one of embodiments 1 to 19, wherein the system is configured to release the erdafitinib at an average rate of 2 mg / day to 4 mg / day.

[0238] 23. The system according to any one of embodiments 1 to 19, wherein the system is configured to release the erdafitinib at an average rate of 4 mg / day.

[0239] 24. The system according to any one of embodiments 1 to 19, wherein the system is configured to release the erdafitinib at an average rate of 2 mg / day.

[0240] 25. The system according to any one of embodiments 1 to 24, wherein the system comprises 500 mg of the erdafitinib (free base equivalent).

[0241] 26. A system according to any one of embodiments 1 to 25, wherein the system is capable of elastically deforming between a relatively straight deployment shape suitable for insertion through a patient's urethra and entering the patient's bladder and a retaining shape suitable for retaining the system within the bladder.

[0242] 27. A system according to any one of embodiments 1 to 26, wherein the system is capable of elastic deformation and comprises a tube having two opposing free ends, wherein the two opposing free ends are guided away from each other when the system is in a low-profile deployment shape and are guided toward each other when the system is in a relatively expanded retention shape.

[0243] 28. A system according to any one of embodiments 1 to 27, wherein the system includes a slender body capable of elastic deformation, the slender body having two opposite free ends, and the two opposite free ends are located within the boundary of a bi-oval-like extended retaining shape.

[0244] 29. A system according to any one of embodiments 1 to 28, wherein the slender body also includes a retaining frame lumen.

[0245] 30. The system of embodiment 29 further comprising a nitinol wire disposed in the retention frame lumen.

[0246] 31. A method of intravesically administering erdafitinib, comprising:

[0247] deploying the drug delivery system into the patient's bladder; and

[0248] Erdafitinib is released from the drug delivery system by osmotic pressure.

[0249] 32. A method of intravesically administering erdafitinib, comprising:

[0250] deploying a system according to any one of embodiments 1 to 30 into a patient's bladder; and

[0251] The erdafitinib is released from the system.

[0252] 33. The method according to embodiment 31 or 32, wherein releasing the Erdafitinib from the system comprises releasing the Erdafitinib from the drug reservoir lumen through the one or more openings driven by osmotic pressure in the drug reservoir lumen.

[0253] 34. A method according to any one of embodiments 31 to 33, wherein the system is capable of elastically deforming into a low-profile deployment shape and being inserted through the urethra and into the patient's bladder, and then assuming a relatively expanded retention shape within the bladder.

[0254] 35. The method according to any one of embodiments 31 to 34, wherein erdafitinib is released into the bladder at an average rate of 1 to 10 mg / day over a period ranging from 7 to 90 days.

[0255] 36. A method of treating non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC) in a cancer patient, comprising:

[0256] inserting a drug delivery system into the bladder of the patient; and

[0257] A therapeutically effective amount of erdafitinib is locally delivered from the drug delivery system to the bladder of the patient driven by osmotic pressure.

[0258] 37. A method of treating non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC) in a cancer patient, comprising:

[0259] inserting a system according to any one of embodiments 1 to 30 into the bladder of the patient; and

[0260] A therapeutically effective amount of erdafitinib is delivered locally from the system into the bladder of the patient.

[0261] 38. The method according to embodiment 36 or 37, wherein the local delivery of Erdafitinib comprises releasing the Erdafitinib from the system at a release rate of about 1 mg / day to about 6 mg / day, such as 2 mg / day to 4 mg / day.

[0262] 39. The method according to any one of embodiments 36 to 38, wherein the system is maintained in the patient's bladder for up to 90 days and then optionally replaced with another system that releases erdafitinib.

[0263] 40. A method of treating a cancer patient with (i) recurrent, non-muscle invasive or muscle invasive bladder urothelial carcinoma, (ii) high-risk or intermediate-risk papillary bladder urothelial carcinoma, or (iii) muscle invasive bladder urothelial carcinoma staged cT2-T3a, comprising:

[0264] inserting a drug delivery system into the bladder of the patient; and

[0265] A therapeutically effective amount of erdafitinib is delivered locally from the drug delivery system into the bladder of the patient, particularly driven by osmotic pressure.

[0266] 41. A method of treating a cancer patient with (i) recurrent, non-muscle invasive or muscle invasive bladder urothelial carcinoma, (ii) high-risk or intermediate-risk papillary bladder urothelial carcinoma, or (iii) muscle invasive bladder urothelial carcinoma staged cT2-T3a, comprising:

[0267] inserting a system according to any one of embodiments 1 to 30 into the bladder of the patient; and

[0268] A therapeutically effective amount of erdafitinib is delivered locally from the system into the bladder of the patient.

[0269] 42. The method of embodiment 40 or 41, wherein prior to local delivery of erdafitinib into the bladder, the patient undergoes transurethral resection of bladder tumor (TURBT) to reduce the total tumor size to less than or equal to 3 cm.

[0270] 43. The method according to any one of embodiments 40 to 42, wherein the local delivery of Erdafitinib comprises releasing the Erdafitinib from the system at a release rate of about 1 mg / day to about 6 mg / day, such as 2 mg / day to 4 mg / day.

[0271] 44. The method according to any one of embodiments 40 to 43, wherein the system is maintained in the patient's bladder for up to 90 days and then optionally replaced with another system that releases erdafitinib.

[0272] 45. A method of treating a Bacillus Calmette-Guerin (BCG) experienced patient with recurrent high-grade Ta / T1 bladder urothelial carcinoma within 18 months of completion of prior BCG therapy, the method comprising:

[0273] inserting a drug delivery system into the bladder of the patient; and

[0274] A therapeutically effective amount of erdafitinib is delivered locally from the drug delivery system into the bladder of the patient.

[0275] 46. ​​A method of treating a Bacillus Calmette-Guerin (BCG) experienced patient with recurrent high-grade Ta / T1 bladder urothelial carcinoma within 18 months of completion of prior BCG therapy, the method comprising:

[0276] A therapeutically effective amount of Erdafitinib is locally delivered to the bladder of the patient from the system, in particular from the system according to any one of Embodiments 1 to 30 inserted into the bladder of the patient.

[0277] 47. The method according to embodiment 45 or 46, wherein the local delivery of Erdafitinib comprises releasing the Erdafitinib from the system at a release rate of about 1 mg / day to about 6 mg / day, such as 2 mg / day to 4 mg / day.

[0278] 48. The method according to any one of embodiments 45 to 47, wherein the system is maintained in the patient's bladder for up to 90 days and then optionally replaced with another system that releases erdafitinib.

[0279] 49. The method of any one of embodiments 36 to 48, wherein the patient has at least one FGFR2 genetic alteration and / or FGFR3 genetic alteration.

[0280] 50. Erdafitinib lactate, in particular erdafitinib L-lactate.

[0281] 51. A pharmaceutical composition comprising erdafitinib lactate, particularly erdafitinib L-lactate, and one or more excipients.

[0282] 52. A pharmaceutical composition according to embodiment 51, wherein the composition is in the form of a tablet, in particular in the form of a mini-tablet.

[0283] Example

[0284] Example 1. Screening of materials and API forms for erdafitinib release

[0285] A variety of polymer materials were tested to determine their suitability as materials of construction for the main body of the elastic system for the release of various erdafitinib formulations. Materials included silicone and several thermoplastic polyurethanes (TPUs) manufactured by Lubrizol Life Science (Bethlehem, PA). The results are shown in Table 1.

[0286] Table 1: In vitro permeation

[0287]

[0288] In Table 1, "O" is permeable, "Δ" is barely permeable, and "X" is impermeable. This information can be used to select permeation system housing materials of construction and design that can be used with various possible erdafitinib forms / formulations.

[0289] Example 2. Sample mini-tablet formulation

[0290] Table 2 shows selected aspects and embodiments of mini-tablet formulations for use with the disclosed drug delivery system. The blends of Table 2 were used for tablets having a target tablet weight of 20 mg and a drug load of 70 wt%.

[0291] Table 2

[0292] Weighing mass (g) weight% Erdafitinib Granules 3692.000 71.43% Copovidone (eg, Kollidon VA64) 667.280 12.91% Microcrystalline cellulose (e.g., Avicel PH105) 667.280 12.91% Colloidal silicon dioxide (e.g., Aerosil 200P) 12.920 0.25% Magnesium Stearate 129.220 2.5% total 5168.700 100.00%

[0293] The Erdafitinib particles consist of 98 wt% Erdafitinib mono-L-lactate and 2 wt% HPMC (eg, HPMC290 15 mPa.s).

[0294] Preparation: All compounds were sieved through a 600 μm sieve. Erdafitinib granules, copovidone, microcrystalline cellulose and colloidal silicon dioxide were weighed and mixed for 10 minutes. The mixture was sieved through a 600 μm sieve. Magnesium stearate was added and the blend was mixed for 5 minutes. The resulting blend was tableted.

[0295] Example 3. Metabolism and Pharmacokinetics of Erdafitinib Delivered Intravesically

[0296] Erdafitinib was determined to be sufficiently stable in freshly collected human, minipig, and rat urine for 6 hours at 37°C, indicating that the drug is stable in urine between urination cycles.

[0297] In vitro protein binding indicated that erdafitinib was present in urine primarily in free form. The percentage of erdafitinib free base in urine of rats, minipigs, and humans was 84%, 97%, and 95%, respectively, and was independent of concentration. Erdafitinib was found to bind less to AGP than to albumin. Albuminuria / proteinuria had minimal effect on the % free form in urine.

[0298] In vitro binding of Erdafitinib to normal / tumor bladder tissues showed a significant free fraction. The free fraction of Erdafitinib in minipig bladder tissue was 79%, which was twice that in rats (33%) and humans (39%). In tumor tissue, the free fraction was 40%.

[0299] Bladder instillation studies in pigs and rats showed good distribution from urine to the bladder, especially to the urothelium. Low systemic bioavailability was observed after topical bladder administration (approximately 5% in rats and 12% in minipigs).

[0300] Based on these studies, erdafitinib is stable in urine and present as a high free fraction, so this should result in desirable exposure to bladder tumors. For intravesical administration, erdafitinib appears to have favorable drug metabolism and pharmacokinetic properties.

[0301] Example 4: Pharmacokinetics of Single-Dose Intravesical Erdafitinib Administration in Rats Bearing Orthotopic Bladder Tumors PK and PD .

[0302] The purpose of Example 4 was to compare the PK and PD effects of topical bladder administration versus oral administration of erdafitinib in nude rats bearing human UM-UC-1 bladder xenografts. Animals were given a single oral dose (20 mg / kg erdafitinib in a 10% weight / volume (w / v) HP-β-CD solution) of erdafitinib or a 1-hour intravesical instillation (6 mg / kg erdafitinib in a 10% w / v HP-β-CD solution) of erdafitinib into the bladder. Extracellular signal-regulated kinase (ERK) 1 / 2 phosphorylation was assessed at various time points after administration / instillation as a PD marker of FGFR kinase inhibition in the tumor. PK analysis of tumor and plasma samples was performed at 2 hours, 7 hours, 48 ​​hours, and 120 hours after a single 6 mg / kg intravesical administration or 20 mg / kg oral dose of erdafitinib. Additionally, erdafitinib was orally administered to a group of nude rats bearing subcutaneous (sc) tumors (UM-UC-1), and the concentrations in plasma and tumors were measured at 2, 7, 48, and 120 hours after dosing.

[0303] Intravesical administration resulted in mean erdafitinib exposure levels comparable to the 20 mg / kg oral dose (Table 3). Approximately 1 / 2 of the exposure levels were detected at 2 and 7 hours in subcutaneous (sc) tumors from orally dosed rats compared to orthotopic tumors from orally dosed rats, however, this reflects the lower commensurate plasma exposures observed in the same group of rats ( Figure 4 ).

[0304] Table 3. Effects of Erdafitinib on the immune response in naive nude rats, UM-UC-1 bearing rats and rats after a single oral or intravesical dose of Erdafitinib. Plasma and tumor exposure levels in nude rats with UM-UC-1 subcutaneous tumors .

[0305]

[0306]

[0307] HP-β-CD, hydroxypropyl β-cyclodextrin; IVES, intravesical (bladder instillation); LLOQ, lower limit of quantitation; PO or po, oral.

[0308] Values ​​are means with standard deviations in parentheses. Mean exposures were lower (<35 ng / g) at the 48 and 120 hour time points. Erdafitinib was dosed as a 10% w / v HP-β-CD solution.

[0309] a LLOQ serum = 0.05 ng / mL

[0310] b LLOQ tumor = 2 ng / g

[0311] cAverage = tumor concentration (ng / g) / plasma concentration (ng / mL)

[0312] The effect of a single 20 mg / kg oral dose or 6 mg / kg intravesical dose of erdafitinib on ERK1 / 2 phosphorylation in orthotopic bladder UM-UC-1 tumors was evaluated by capillary immunoblotting at different time points. Proteins in tumor sample lysates collected 2 hours, 7 hours, 48 ​​hours, and 120 hours after treatment with erdafitinib or vehicle were separated by capillary electrophoresis and probed with antibodies detecting phosphorylated (p)ERK1 / 2 and total ERK1 / 2. The signal for pERK1 / 2 was divided by the total ERK1 / 2 signal in the same sample, and the average of the pERK1 / 2 values ​​for the corresponding vehicle-treated samples was set as a relative value of 1. At each time point, the pERK / ERK ratio of each tumor sample was divided by the average pERK / ERK ratio from the corresponding control sample. There was 1 exception, because there was no vehicle-treated sample at the 120 hour time point, the pERK / ERK ratio of the erdafitinib-treated sample at the 120 hour time point was divided by the average of the 48 hour vehicle-treated group.

[0313] Both the 6 mg / kg intravesical dose and the 20 mg / kg oral dose of erdafitinib resulted in a statistically significant decrease in ERK1 / 2 phosphorylation in UM-UC-1 tumors at 2 hours post-dose ( Figure 5 , Table 4). Although not statistically significant, pERK levels were also lower in erdafitinib-treated tumors compared to vehicle-treated tumors at 7 and 48 hours, however by 120 hours, levels of pERK1 / 2 were comparable to those of vehicle-treated rats.

[0314] Table 4. pERK / ERK levels in UMUC1 orthotopic tumors after a single oral or intravesical dose of erdafitinib flat .

[0315]

[0316] ANOVA, analysis of variance; ERK, extracellular signal-regulated kinase; IVES, intravesical; NA, not applicable; pERK, phosphorylated extracellular signal-regulated kinase; po, oral.

[0317] "Zero dose" animals were administered vehicle.

[0318] a Ratio of the mean group value of pERK / ERK divided by the mean of the vehicle-treated group. Standard deviations are in parentheses.

[0319] b One-way ANOVA, Dunnett's multiple comparison test.

[0320] c Values ​​were divided by the mean of the 48 h vehicle-treated group.

[0321] Together, these data demonstrate that intravesical administration of erdafitinib provides adequate tumor PK / PD while significantly reducing exposure in plasma, thereby reducing the potential for on-target, off-tumor toxicity compared with oral therapy.

[0322] Example 5: Continuous perfusion studies in an orthotopic bladder cancer model .

[0323] Infusion studies: On day 1, the bladders of study animals were cannulated and the animals were allowed to recover for 3 days. On day 5, UM-UC-1 cells (2×10 6 cells) were injected into the lateral wall of each bladder. After a 2-day tumor growth period, erdafitinib was instilled continuously for 5 days, followed by necropsy within 24 hours. Based on the in vitro results, target urine concentrations of 0.5 μg / mL, 1.0 μg / mL, and 5.0 μg / mL were used in the instillation experiments. Figure 7 Body weight, daily urine production, and daily water consumption were recorded. At necropsy, plasma samples, bladder photographs, and bladder weight measurements were recorded. Total bladder weight after necropsy, consisting of normal bladder tissue plus urothelial tumor, was used to determine the effect of erdafitinib on tumor growth.

[0324] Human-derived tumor cells, when implanted into the bladder wall of athymic rats, grow rapidly. Within 7 days of implantation, the tumors occupy a large portion of the urothelial surface and increase total bladder weight by up to 7-fold ( Figure 6 ). Therefore, total bladder weight is an accurate measure of drug response.

[0325] Five days of continuous erdafitinib infusions at nominal urine concentrations of 0.5 μg / mL, 1.0 μg / mL, and 5.0 μg / mL were generally well tolerated. Body weight changes during the study were shown in Figure 8 An initial small decrease in body weight, <5% (Days 1-3), was observed in most groups, including vehicle controls, due to the effects of the bladder catheterization procedure. Minimal body weight changes were noted following intravesical tumor cell injection on Day 5. Transfer to metabolic cages and initiation of bladder instillations resulted in the second smallest decrease in body weight that was unrelated to instillation fluid drug concentration. No visible signs of abnormal behavior or clinical symptoms were observed in any treatment group based on cage-side observations.

[0326] The percentage reduction in relative tumor weight between the control and drug infusion groups was determined as an initial measure of efficacy. Bladder tissue and tumor samples were also submitted for analysis of FGFR signaling activity by determining phosphorylated fibroblast growth factor receptor substrate (FRS) 2a levels and pERK to ERK ratios. Additional urine, plasma, and bladder samples were collected to determine erdafitinib concentrations using an established liquid chromatography-tandem mass spectrometry (LC-MS / MS) method. The mean bladder weight changes of animals receiving different erdafitinib concentrations are shown in Fig. 9 A significant dose-dependent decrease in bladder weight was observed in the erdafitinib treated groups when compared to the vehicle control group (**p<0.01 for 0.5 μg / mL of erdafitinib, ***p<0.001 for 1.0 μg / mL and 5 μg / mL of erdafitinib at nominal urine concentrations) .

[0327] Example 6: Dosage of Erdafitinib in Instilled Athymic Rats with RT-112 Implanted into the Bladder Wall Reaction evaluation .

[0328] Perfusion studies: Experimental study design and Example 5 ( Figure 7 ) except that the infusion was continued until the time of necropsy on day 14. Treatment with six days of continuous infusion of erdafitinib at nominal urine concentrations of 0.25 μg / mL, 0.5 μg / mL, and 1.0 μg / mL was well tolerated during the experimental period. The body weight changes observed during the study are shown in Fig.10 Mild weight loss was observed during the study, with a maximum mean range of up to -3% in the erdafitinib-treated group on Day 11.

[0329] The effect of intravesical erdafitinib exposure on tumor growth as determined by changes in total bladder weight is shown in Fig.11 Mean bladder weights tended to decrease with increasing erdafitinib concentrations, but the decreases were not statistically significant for the 0.25 μg / mL and 0.5 μg / mL dose groups relative to vehicle control animals. Significant bladder weight reductions were observed in animals receiving the 1.0 μg / mL perfusate concentration compared to vehicle control (*p<0.05).

[0330] Evaluation of the dose response of erdafitinib (0.25 μg / mL-5 μg / mL) in intravesical athymic rats with UM-UC-1 or RT-112 cell lines implanted into the bladder wall demonstrated that the dosing regimen of erdafitinib was generally well tolerated. A significant dose-dependent decrease in bladder weight was observed in the erdafitinib-treated group when compared to the vehicle control group, demonstrating that intravesical instillation of erdafitinib reduced tumor growth.

[0331] Example 7: Intravesical Pharmacokinetics and Distribution Studies in Rats and Minipigs .

[0332] Systemic and urinary bladder PK studies were performed following a single intravesical (bolus) administration of erdafitinib formulations in solution (HP-β-CD) to rats and minipigs. These studies were initially performed to determine drug exposure in bladder tissue, urine, and plasma. In addition, macroscopic and microscopic examinations of bladder tissue were evaluated to determine if there were any local effects of the drug or formulation under study. The purpose of Example 7 was to determine the feasibility of intravesical therapy of erdafitinib with bladder instillations of erdafitinib.

[0333] Single intravesical dose PK in rats: Systemic and bladder PK of erdafitinib was determined in female Sprague-Dawley rats following intravesical administration of erdafitinib solution at 2 mg, 6 mg, and 18 mg per kg body weight. Rats were maintained anesthetized using isoflurane (2%-4%), a catheter was introduced into the urethra to reach the bladder, and erdafitinib solution (10% w / v HP-β-CD in citrate buffer pH 5.5) was instilled into the rat bladder via the catheter. Solution formulations of various strengths were prepared so that a volume of 0.5 mL was administered to each rat bladder to doses of 2 mg / kg, 6 mg / kg, and 18 mg / kg. The corresponding doses for the nominal drug amount were 0.5 mg, 1.5 mg, and 4.5 mg, respectively. After 1 hour post-instillation, the rats were transferred to metabolic cages to collect samples for PK determination. Blood samples were collected from the tail vein at 24 hours, 48 ​​hours, 72 hours, 96 hours and 168 hours after completing the 1 hour contact time of the compound after administration (3 rats at each time point). At each blood sampling time point, bladder samples were collected from each rat for drug analysis. In addition, the bladder collected at 96 hours in the 18mg / kg dosage (high dose) group was evaluated with a microscope. Urine was collected from all rats and was limited to the initial 0 hour-6 hours after administration.

[0334] In plasma, almost all samples were below the limit of quantitation (0.02 ng / mL) for the 2 mg / kg and 6 mg / kg dose groups. For the 18 mg / kg dose group, some measurable concentrations (between 0.0303 ng / mL and 0.106 ng / mL) were observed at 24 hours, 48 ​​hours, and 72 hours, but at 96 hours and 168 hours, all samples were below the limit of quantitation. In the bladder, concentrations can be measured up to 72 hours for the 2 mg / kg and 6 mg / kg dose groups, and up to 168 hours for the 18 mg / kg dose group. The concentration was highest at the 24 hour time point, after which the concentration decreased. Dose linearity could not be observed. The exposure between the test doses was similar. For the 2 mg / kg, 6 mg / kg, and 18 mg / kg dose groups, the percentage of compounds eliminated in the urine as unchanged drugs (within the first 6 hours) totaled 23.5%, 19%, and 50.3%.

[0335] Systemic and bladder PK of continuous intravesical erdafitinib in rats: Systemic and bladder PK of erdafitinib was determined in female Sprague-Dawley rats following continuous intravesical infusion of an aqueous solution of erdafitinib. The rat bladder (5 groups of rats, n=3 / group) was surgically cannulated under anesthesia, and the catheter was externalized, tunneled subcutaneously, and connected to a vascular access harness (VAH) at the neck. The rats were transferred to individual metabolic cages with free access to food and water during a 1-week recovery period after surgery. On the day of the study, erdafitinib solution (0.1 mg / mL, 0.1 mL / hour, citrate buffer pH 5.5 containing 5% w / v HP-β-CD) was instilled through the rat bladder via a catheter for more than 72 hours. The first group (n=3) was sacrificed 24 hours after instillation, and 2 of the remaining 4 groups were sacrificed 48 hours and 72 hours after instillation. For the last 2 groups, the infusion was stopped at 72 hours, and the groups were sacrificed at 96 hours and 120 hours to determine the drug clearance phase from the bladder. Plasma samples and bladder samples were collected at all time points. Urine was collected from the third group for drug analysis during the 48-72 hour infusion period. The plasma concentrations of rats after 72 hours of bladder infusion of erdafitinib solution (0.1 mg / mL, 0.1 mL / hour, cumulative dose 0.72 mg) are shown in Table 1. Fig. 12A After cessation of instillation at 72 hours, no levels were detected in the samples until 120 hours (i.e., another 48 hours) (below the limit of quantification; 0.2 ng / mL). The bladder levels of rats 72 hours after bladder instillation of erdafitinib solution (0.1 mg / mL, 0.1 mL / hour, cumulative dose 0.72 mg) were shown Fig. 12B The bladder of rats instilled with a 0.1 mg / mL erdafitinib solution showed no changes, and the strength of the formulation was considered to be tolerable. For urine collected during the 48-72 hour instillation interval, the average daily urine concentration was measured to be approximately 10,000 ng / mL.

[0336] Table 5. Plasma and bladder systemic exposure of erdafitinib following intravesical instillation .

[0337] parameter plasma bladder concentration plasma bladder <![CDATA[AUC 0-24h (ng·h / mL)]]> 8.09 20,200 <![CDATA[C 24h (ng / mL)]]> 0.674 1,680 <![CDATA[AUC 0-48h (ng·h / mL)]]> 27.2 61,100 <![CDATA[C 48h (ng / mL)]]> 0.916 1,730 <![CDATA[AUC 0-72h (ng·h / mL)]]> 48.1 111,000 <![CDATA[C 72h (ng / mL)]]> 0.829 <![CDATA[2,420 a ]]> <![CDATA[AUC 0-96h (ng·h / mL)]]> 48.1 126,000 <![CDATA[C 96h (ng / mL)]]> BQL 56.9 <![CDATA[AUC 0-120h (ng·h / mL)]]> 48.1 127,000 <![CDATA[C 120h (ng / mL)]]> BQL 10.7

[0338] AUC 0-xh , the area under the plasma concentration-time curve from the time of administration until x hours; C xh , plasma concentration at time x; BQL, below limit of quantitation.

[0339] aThe average daily urine concentration at this time point is approximately 10,000 ng / mL.

[0340] Results demonstrated significant bladder tissue erdafitinib uptake and maintenance of high bladder levels with minimal systemic exposure during continuous slow infusion of erdafitinib.

[0341] Systemic and bladder PK of continuous intravesical erdafitinib in pigs: Systemic and bladder PK of erdafitinib was evaluated in five sows (native Yorkshire crossbreed pigs) after continuous intravesical infusion of erdafitinib aqueous solution. On day -7, a catheter was surgically placed in the bladder of each animal. The distal end of the catheter was anchored to the subcutaneous site and connected to a vascular access port (VAP). The port was fixed and the animal recovered. Each animal was then equipped with a portable infusion pump, which was connected to the bladder catheter via the VAP. The dosing formulation (22.5 μg / mL erdafitinib solution in 50 mM citrate buffer pH 6.0) was prepared daily and sterile filtered and analyzed daily to confirm the concentration. The dosing formulation was infused into the bladder at a constant rate of 12.5 mL / hour for 6 consecutive days (2 animals) and 8 consecutive days (3 animals). All excreted urine was collected at 24-hour intervals on the 6th or 8th day. Blood samples were collected daily from study day 1 to day 8. Bladder tissue samples were collected from each animal at necropsy. Samples obtained from all animals were analyzed for erdafitinib using a qualified LC-MS / MS method. Based on formulation analysis for all days, the average daily dose administered to each animal was 7.06 mg to 7.56 mg, and the overall average dose was 7.3 mg / day. Based on average body weight (pre-dose), the administered dose was 0.22 mg / kg / day.

[0342] On days 2 to 8, mean (±SD) erdafitinib urine concentrations ranged from 1,255±554 ng / mL to 873±179 ng / mL ( Fig.13 The mean (±SD) erdafitinib plasma concentrations from day 2 to day 8 are shown in Fig.14 The mean (±SD) daily urine output was 966±253 mL over the 7-day period of the study. Although inter- and intra-animal variations in daily urine production were observed, no significant trends in urine production were observed over the treatment period. The urinary recovery of erdafitinib was relatively consistent in all animals, averaging 910±812 ng to 1,135±760 ng on days 2 to 8. Daily erdafitinib recovery averaged 15.7%±5.67% of the average daily amount of erdafitinib administered.

[0343] Mean erdafitinib concentrations in full-thickness bladder tissue were measured on Days 6 and 8 (end of instillation) and values ​​ranged from 315 ng / g to 998 ng / g and 346 ng / g to 2,688 ng / g, respectively. Erdafitinib concentrations were measured in the urothelium and underlying tissue layers (i.e., muscle). These data indicate that there is a >10-fold higher concentration of erdafitinib in the urothelial layer of the bladder when compared to the underlying tissue layers, suggesting that the drug is primarily retained in the urothelium.

[0344] Table 6. Erdafitinib bladder tissue concentrations in pigs 7 days after intravesical instillation of Erdafitinib .

[0345]

[0346] conc, concentration; Rem layer, the tissue layer below the bladder; Urothel layer, bladder urothelium.

[0347] Example 8: Stability and protein binding studies .

[0348] Stability in Urine: As part of the equilibrium dialysis study, Erdafitinib was spiked into urine at 1 μg / mL, 3 μg / mL, and 5 μg / mL and incubated (in triplicate) for 6 hours at 37°C. At the end of the 6-hour post-dialysis incubation, the drug was analyzed and the recovery was calculated relative to the spiked concentration. The percentage recovery of Erdafitinib in the study ranged from 89% to 98% in human urine, 90% to 95% in rat urine, and 92% to 93% in minipig urine, indicating that Erdafitinib is stable in urine. These results suggest that Erdafitinib will remain stable in urine within the bladder to provide exposure to tumor and bladder tissue.

[0349] Example 9: Prototype Development .

[0350] Based on experiments, including animal studies, release rates of 1 mg / day, 2 mg / day, 4 mg / day, and 6 mg / day were selected for further development. Designs that could be used for 30 and 90 day durations were evaluated. A 30-day design was performed to provide a higher drug release rate that also exceeded the 90-day effective load capacity of the device. The minimum target release rate was defined as the rate required to produce an average erdafitinib urine concentration of 1 μg / mL. Higher release rates were also evaluated to increase tumor exposure and assess local tolerance and systemic exposure tendencies. Additional performance indicators included urine pH, urine volume, and urine composition independence.

[0351] Erdafitinib exhibits significant pH-dependent solubility within the normal urine pH range of 5.5 to 7. As a result, different drug forms and minitablet excipient combinations were evaluated to minimize the effects of urine pH and composition on systemic release rates.

[0352] A factorial design-based screening was first completed to evaluate the full range of possible release rates and pH effects. Approximately 900 combinations of device polymers and erdafitinib drug forms were tested using a powder-packed short core system, which was a 2-cm version of a design known to be accurately scaled to the full 15-cm length. The drug forms evaluated included erdafitinib free base, erdafitinib HCl salt, erdafitinib L-lactate, and erdafitinib free base plus HP-β-CD.

[0353] Material screening

[0354] In general, materials that are impermeable to erdafitinib (API) are suitable for use in permeation systems. Platinum-cured silicone, thermoplastic polyurethane (TPU), and ethylene vinyl acetate (EVA) materials were screened (Table 7). Test articles were filled with formulated API (powder or tablet), sealed, placed in foil bags, and gamma irradiated (nominal 35 kGy). The system was placed in simulated urine (pH 6.8), stored at 37°C, and sampled regularly. The amount of API in each sample was determined by high performance liquid chromatography (HPLC) analysis.

[0355] Table 7. Material screening .

[0356]

[0357]

[0358] EVA, ethylene vinyl acetate; NA, not available; TPU, thermoplastic polyurethane

[0359] The permeability screening results are shown in Fig.15 Materials suitable for use in the osmotic system are impermeable to the API. Silicone was used as the tubing material for the osmotic system and was also suitable as the osmotic tubing material for all 4 erdafitinib forms. Based on its impermeable properties, silicone was selected as the material for further development of the osmotic prototype.

[0360] Infiltration system

[0361] Silicone tubing was selected for the osmotic system and the four API forms were screened with and without additional osmotic agents (e.g., sodium chloride, potassium chloride, potassium bicarbonate, disodium hydrogen phosphate dihydrate, sodium sulfate, and L-(+)-sodium tartrate dihydrate) that were capable of producing a constant water flux through the silicone tubing for at least 30 days. The short wick osmotic system was tested with the four API forms alone and with added osmotic agents. The HCl salt form was not tested with sodium chloride or potassium chloride due to the common ions between the API and the osmotic agent. The short wick system that showed the most promising release rate was the L-lactate API form without added osmotic agent.

[0362] Table 8. Overview of prototypes tested in minipigs .

[0363]

[0364] Permeation system with erdafitinib L-lactate

[0365] Two osmotic system prototypes with erdafitinib L-lactate were tested in minipigs (Prototype 4): Osmotic (orifice + end plug), 0.2 mm wall, erdafitinib L-lactate, tablet (20% insoluble); Prototype 5: Osmotic (orifice + end plug), 0.2 mm wall, erdafitinib L-lactate, tablet (soluble)); see Fig.16A and Fig. 16B ). The drug ingredient formulations are described in Table 9. Both prototypes included a dual-lumen silicone tube (2.64 mm large lumen ID, 0.2 mm wall thickness), a 150 μm orifice, 2 end plugs, a 15 cm drug core, and a wire structure as a retention feature. Table 10 describes the drug ingredient payload for each prototype. Prototype 4 was IVR tested using simulated urine of 3 different pH ranges as the release medium: pH 5, 6.8, and 8 (n = 3 systems tested in each medium). Prototype 5 was tested in simulated urine at pH 6.8 (n = 2 systems tested in IVR). The IVR curve of prototype 4 showed good consistency between simulated urine of pH 5, 6.8, and 8, and almost zero-order release over a duration of 90 days ( Fig.17 ). The IVR curve of prototype 5 was tested in simulated urine at pH 6.8 with only 2 replicates ( Fig.18 ). The prototype also showed near zero-order release over a 90-day duration.

[0366] Table 9. Erdafitinib mono-L-lactate mini-tablet composition (drug ingredients) .

[0367]

[0368] API, active pharmaceutical ingredient; NA, not applicable; w / w, weight / weight.

[0369] Table 10. Final system parameters .

[0370] parameter Prototype 4 Prototype 5 Tablet quality 932mg 961mg API Quality 620mg FBE 726mg FBE

[0371] FBE, free base equivalent.

[0372] Pharmacokinetic evaluation in miniature pigs

[0373] The osmotic design released erdafitinib in minipigs at a rate designed to provide a target urine concentration of 1 μg / mL or higher. The zero-order system demonstrated in vitro release rates (defined as release at a constant rate for at least 30 days) up to 2 mg / day (>90 days of duration). Inter- and intra-device release rate variability was minimal with the zero-order system.

[0374] Based on the short core data, a series of 200 full-length systems were developed and tested to confirm the short core results. A subset of these data was tested in minipigs to determine the in vivo release rate characteristics of the osmotic design and obtain the release rates required to achieve the target urine concentrations. The in vivo results largely confirmed the in vitro findings and demonstrated that in vitro release rates of 2 mg / day to 4 mg / day were sufficient to maintain the target erdafitinib urine concentrations. Fig.17 and Fig.18 The in vitro release properties of representative osmotic systems selected for minipig studies are summarized. Fig.19 Urine concentration versus time profiles for the same systems are summarized.Prototypes 4 and 5 are representative zero-order permeation designs utilizing permeation-based release.

[0375] Example 10: Chemistry, stability, formulation and device development .

[0376] Erdafitinib was designated as number JNJ-42756493, with the suffix -AAA denoting the free base form and the suffix -AFK denoting the mono-L-lactate salt.

[0377] A summary of the solid state properties of both the free base and the L-lactate salt is provided in Table 11. The physical stability of the L-lactate salt after storage in an open dish for 6 weeks under different conditions was evaluated by differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), thermogravimetric analysis (TGA) and infrared (IR). The product was found to be crystallographically stable. No evidence of dissociation or form conversion was found (Table 12).

[0378] Table 11. Summary of solid state properties of JNJ-42756493 free base and L-lactate .

[0379]

[0380] DVS, dynamic vapor sorption; RT, room temperature; TGA, thermogravimetric analysis; XRPD, X-ray powder diffraction.

[0381] Table 12. Summary of solid state stability of mono-L-lactate JNJ-42756493-AFK .

[0382] condition TGA weight loss %w / w < 135℃ XRPD IR DSC Max(℃) Day 0 0.2 Cryst.,Ref Cryst.,Ref 173.4 RT / <5%RH 0.0 ~Ref ~Ref 173.8 RT / 56%RH 0.1 ~Ref ~Ref 174.2 RT / 75%RH 0.0 ~Ref ~Ref 173.9 50℃ 0.0 ~Ref ~Ref 174.2 40℃ / 75%RH 0.0 ~Ref ~Ref 174.3

[0383] Cryst.Ref., crystal reference; DSC, differential scanning calorimetry; IR, infrared; Max, maximum value; RH, relative humidity; RT, room temperature; TGA, thermogravimetric analysis; w / w, weight / weight; XRPD, X-ray powder diffraction.

[0384] Formulation-Device Development

[0385] Formulation development focused on the erdafitinib L-lactate mini-tablet concept (refer to Table 13 for exemplary concepts).

[0386] Table 13. JNJ-42756493-AFK (Erdafitinib mono-L-lactate) mini-tablet composition .

[0387] Components Weight / weight% Function API granules (Erdafitinib L-lactate, HPMC E15) 71.43(70.00,1.43) API, Adhesives Kollidon VA64 12.91 Adhesives MCC-Avicel PH105 12.91 Adhesives Colloidal Silica (Aerosil 200) 0.25 Glidants Magnesium Stearate 2.5 Lubricants total 100

[0388] API, active pharmaceutical ingredient; w / w, weight / weight.

[0389] Evaluation of an osmotic silicone system (osmotically pressure driven, with orifices).

[0390] L-lactate has unexpectedly high solubility over a wide pH range and unexpectedly has osmotic properties. The solubility of L-lactate in water at 37°C is shown as a function of pH ( Fig. 20A ) and its solubility in simulated urine as a function of pH ( Fig. 20B ).

[0391] Example 11: Synthesis of Erdafitinib L-lactate .

[0392] Synthesis of Erdafitinib L-lactate: Erdafitinib mono-L-lactate ( Fig.21 ). Crystallization was carried out using API seeding.

[0393] Procedure 1

[0394] Table 14: Materials List :

[0395] Material MW ratio JNJ-42756493-AAA 446.55 1mol L-Lactic Acid 90.08 1.02mol / mol Isopropyl alcohol (IPA) 60.1 1.006L / mol water 18.02 0.11178L / mol Isopropyl alcohol (IPA) 60.1 1.1178L / mol JNJ-42756493-AFK 536.63 5.4g / mol Isopropyl alcohol (IPA) 60.1 0.54L / mol

[0396] Wet grinding procedure :

[0397] Dissolved API

[0398] Erdafitinib base was added to the reactor.

[0399] 1.02 mol L-lactic acid / mol erdafitinib base was added.

[0400] 1.006 L of isopropanol / mol of Erdafitinib base was added to the reactor. 0.11178 L of water / mol of Erdafitinib base was added to the reactor.

[0401] Dissolve and maintain at 70° C. Complete dissolution was confirmed visually.

[0402] The receiving vessel was set to a jacket temperature of 80°C.

[0403] Perform polish filtration at at least 70°C and maintain polish filtration. Rinse the filter with 1.1178 L isopropanol / mol erdafitinib base.

[0404] Wait until the temperature in the receiving reactor stabilizes to 80°C Establishing seeding conditions Cool to 69°C at 0.3°C / min

[0405] Wait until the temperature stabilizes

[0406] Seeding with 1m% seed material (5.4 g / mol)

[0407] Wait 4 hours

[0408] Cool to wet grinding conditions Cool to 20°C at 0.2°C / min

[0409] Wait 1 hour

[0410] The suspension was wet milled for 60 min using a high shear mill configured as 2P-4M (CDMP scale) and the reactor was heated to 35 °C at 0.2 °C / min.

[0411] Keep for 30 minutes and cool to 20℃ at 0.2℃ / min

[0412] The reactor was heated to 40°C at 0.2°C / min.

[0413] Keep for 30 minutes and cool to 20℃ at 0.2℃ / min

[0414] Final cooling and filtration Cool down to 5℃ at 0.2℃ / min

[0415] Hold at 5°C for >3 hours before filtration - holding point

[0416] Filter cake washing and drying

[0417] The wet cake was washed with isopropanol: 0.54 L isopropanol / mol JNJ-42756493-AFK (erdafitinib mono-L-lactate).

[0418] Wash through the reactor to slightly pre-cool the wash solvent

[0419] Wash as quickly as possible after removing the mother liquor

[0420] The solid was dried in a vacuum oven at 40 °C for >24 h.

[0421] Procedure 2

[0422] Table 15: Materials List :

[0423] Material MW ratio JNJ-42756493-AAA (Erdafitinib Base) 446.55 1mol L-Lactic Acid 90.08 1.02mol / mol Isopropyl alcohol (IPA) 60.1 1.006L / mol water 18.02 0.11178L / mol Isopropyl alcohol (IPA) 60.1 1.1178L / mol JNJ-42756493-AFK(micronized) 536.63 24.39 g / mol Isopropyl alcohol (IPA) 60.1 0.54L / mol

[0424] program :

[0425] Dissolved API

[0426] Add erdafitinib base to the reactor

[0427] Add 1.02 mol L-lactic acid / mol erdafitinib base

[0428] Add 1.006 L isopropanol / mol erdafitinib base to the reactor

[0429] Add 0.11178 L water / mol erdafitinib base to the reactor

[0430] Dissolve and maintain at 70°C. Visually confirm complete dissolution

[0431] Set the receiving vessel to a jacket temperature of 80°C

[0432] Fine filter and maintain at least 70°C

[0433] Rinse the filter with 1.1178 L isopropanol / mol erdafitinib base

[0434] Wait until the temperature in the receiving reactor stabilizes to 80 °C.

[0435] Establishing seeding conditions

[0436] Cool to 63°C at 0.3°C / min

[0437] Wait until the temperature stabilizes

[0438] Seeding was performed with 4.5m% micronized seed material (24.39 g / mol).

[0439] Wait 4 hours

[0440] Final cooling and filtration

[0441] Cool down to 5℃ at 0.2℃ / min

[0442] Hold at 5°C for >3 hours before filtration - holding point

[0443] Filter cake washing and drying

[0444] The wet cake was washed with isopropanol: 0.54 L isopropanol / mol JNJ-42756493-AFK (erdafitinib mono-L-lactate).

[0445] Wash through the reactor to slightly pre-cool the wash solvent

[0446] Wash as quickly as possible after removing the mother liquor

[0447] The solid was dried in a vacuum oven at 40 °C for >24 h.

[0448] Example 12: Microtablets containing Erdafitinib Lactate

[0449] Manufacturing process

[0450] The manufacturing process of mini tablets can be described as follows: First, a binder solution is produced by dissolving hydroxypropyl methylcellulose 2910 (HPMC) in purified water until a clear solution without lumps is obtained. Then, the sieved drug substance is transferred to a granulator and fluidized bed granulation (FBG) is performed: the contents are heated while fluidizing, all the binder solutions are sprayed onto the ingredients, and finally the particles are dried after spraying while fluidizing. After FBG, the dried particles are sieved using a suitable screen. Subsequently, the sieved extragranular excipients are added to the particles and blended into a uniform blend for 10 minutes. Then, the sieved magnesium stearate is added to the blend and blended for 5 minutes. The final blend is then pressed into a tablet core using a suitable tablet press, and the tablets are passed through a dust collector and a metal detector.

[0451] DoE studies :

[0452] A Design of Experimental Studies was performed. A main compression force of 10 kN was used to make the DoE-concepts. Hardness, weight variation (% RSD weight, related to tablet defects) and ejection force were investigated for the different concepts.

[0453] The following conclusions can be drawn from this DoE study: 1) SMCC is preferred as a filler; 2) PVPVA, colloidal silicon dioxide (hydrophilic) and magnesium stearate are preferred as a binder, glidant and lubricant, respectively; 3) MCC is preferred as an additional filler / binder.

[0454] Table 16: Exemplary mini-tablet compositions :

[0455]

[0456]

[0457] A summary of the in-process control (IPC) results obtained for Concepts 1-3 is presented in Table 17.

[0458] Table 171: IPC results for DoE concepts 1-3.

[0459]

[0460] When evaluating the IPC results, similar values ​​were observed for the different concepts. A comparison of hardness and ejection force was performed. A higher standard deviation of the ejection force was observed when SSF was used as the lubricant. The hardness and ejection force of concepts 1 and 2 were comparable, with slightly better results for concept 1 (i.e., lower ejection force and better tablet hardness). The variation of hardness with compression force for each concept was studied. The results showed that the manufacturing process for concepts 1 and 2 was very robust. Promising results were also obtained for concept 4. For concept 4, slight flash was observed at higher compression forces. The compression curve of concept 5 showed comparable results to concept 2, but the data for concept 5 was more variable and visually less desirable tablets were observed. In summary, concept 2 was preferred as it was the most robust concept for manufacturability and scale-up.

[0461] Many modifications and other specific implementations of the disclosure set forth herein will be apparent with the benefit of the foregoing description and the teachings presented in the associated drawings. Therefore, it should be understood that the disclosure is not limited to the specific embodiments disclosed, and that modifications and other specific implementations are intended to be included within the scope of the appended claims. Although specific terms are employed herein, these terms are used only in a general and descriptive sense and not for the purpose of limitation.

Claims

1. An intravesical drug delivery system, comprising: an elongated body configured for intravesical insertion into a patient; and a pharmaceutical preparation disposed in the elongated body, the pharmaceutical preparation comprising erdafitinib (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine) or a pharmaceutically acceptable salt thereof, in particular an L-lactate salt of erdafitinib, The drug delivery system is configured to release the erdafitinib from the one or more openings in the elongated body driven by osmotic pressure.

2. The drug delivery system according to claim 1, wherein erdafitinib is present in the form of a mono-L-lactate salt.

3. A drug delivery system according to claim 1 or 2, wherein the elongated body comprises a biocompatible elastomer.

4. The drug delivery system of claim 3, wherein the biocompatible elastomer comprises silicone or thermoplastic polyurethane.

5. The drug delivery system of claim 3, wherein the biocompatible elastomer comprises silicone.

6. The drug delivery system of claim 3, wherein the biocompatible elastomer comprises a platinum-cured silicone elastomer.

7. The drug delivery system according to any one of claims 1 to 6, wherein at least one of the one or more openings in the elongated body is located in a side wall of the elongated body.

8. A drug delivery system according to any one of claims 1 to 7, wherein at least one of the one or more openings in the elongated body is located at a first end and / or an opposite second end of the elongated body.

9. A drug delivery system according to any one of claims 1 to 6, having a single opening located in the side wall of the elongated body at a position between a first end and an opposite second end of the elongated body.

10. The drug delivery system according to any one of claims 1 to 9, wherein the one or more openings have a diameter of about 100 μm to about 200 μm.

11. The drug delivery system of claim 10, wherein the one or more openings have a diameter of about 150 μm.

12. The drug delivery system according to any one of claims 1 to 11, wherein the drug formulation comprises at least one pharmaceutical excipient.

13. drug delivery system according to claim 12, wherein the at least one pharmaceutical excipient comprises or is selected from solubilizing agent, binding agent, diluent (filler), wetting agent, disintegrant, glidant, lubricant, formaldehyde scavenger, permeating agent or any combination thereof.

14. The drug delivery system of claim 12, wherein the at least one pharmaceutical excipient comprises or is selected from a binder, a diluent (filler), a glidant, a lubricant or any combination thereof.

15. The drug delivery system of claim 14, wherein the binder comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone (PVP), vinyl pyrrolidone-vinyl acetate (PVP-VA), or a combination thereof.

16. The drug delivery system of claim 14 or 15, wherein the binder is present in the drug formulation at a total concentration of about 1 wt % to about 30 wt %, about 5 wt % to about 20 wt %, or about 10 wt % to about 15 wt %.

17. The drug delivery system according to any one of claims 14 to 16, wherein the diluent (filler) comprises microcrystalline cellulose, silicified microcrystalline cellulose, calcium hydrogen phosphate or a combination thereof.

18. according to the drug delivery system described in any one of claims 14 to 17, wherein the diluent (filler) is present in the pharmaceutical preparation with a total concentration of about 5 % by weight to about 30 % by weight, about 10 % by weight to about 30 % by weight or about 10 % by weight to about 20 % by weight.

19. The drug delivery system according to claims 14 to 18, wherein the glidant comprises hydrophilic colloidal silica or hydrophobic colloidal silica, in particular hydrophilic colloidal silica.

20. The drug delivery system of any one of claims 14 to 19, wherein the glidant is present in the drug formulation at a total concentration of about 0.05 wt% to about 1 wt%, about 0.1 wt% to about 0.5 wt%, or about 0.25 wt%.

21. A drug delivery system according to any one of claims 14 to 20, wherein the lubricant comprises magnesium stearate or sodium stearyl fumarate or polyethylene glycol.

22. The drug delivery system of any one of claims 14 to 20, wherein the lubricant comprises magnesium stearate.

23. The drug delivery system of any one of claims 14 to 22, wherein the lubricant is present in the drug formulation at a total concentration of about 0.05 wt % to about 5 wt %, about 1 wt % to about 5 wt %, or about 2.5 %.

24. The drug delivery system according to any one of claims 1 to 23, wherein the drug formulation comprises an intragranular composition comprising erdafitinib or a pharmaceutically acceptable salt thereof, in particular a lactate salt of erdafitinib, and at least one intragranular excipient; and an extragranular composition comprising at least one extragranular excipient.

25. The drug delivery system of claim 24, wherein the at least one intragranular excipient and the at least one extragranular excipient do not comprise a common pharmaceutical excipient.

26. The drug delivery system of claim 24 or 25, wherein the at least one intragranular excipient comprises an intragranular binder.

27. A drug delivery system according to any one of claims 24 to 26, wherein the intragranular binder comprises hydroxypropyl methylcellulose.

28. according to the drug delivery system described in any one of claim 24 to 27, wherein the at least one extragranular excipient comprises one or more of an extragranular binder, an extragranular filler (diluent), an extragranular glidant and an extragranular lubricant.

29. The drug delivery system of claim 28, wherein the extragranular binder comprises vinyl pyrrolidone-vinyl acetate.

30. The drug delivery system according to claim 28 or 29, wherein the extragranular diluent (filler) comprises microcrystalline cellulose, silicified microcrystalline cellulose, or a combination thereof.

31. A drug delivery system according to any one of claims 28 to 30, wherein the extragranular glidant comprises hydrophilic colloidal silicon dioxide.

32. A drug delivery system according to any one of claims 28 to 31, wherein the extragranular lubricant comprises magnesium stearate or sodium stearyl fumarate or polyethylene glycol.

33. A drug delivery system according to any one of claims 28 to 32, wherein the extragranular lubricant comprises magnesium stearate.

34. The drug delivery system according to any one of claims 1 to 33, wherein the Erdafitinib L-lactate is present in the pharmaceutical formulation at a concentration of 60 wt% to 91 wt% or 60 wt% to 80 wt%.

35. The drug delivery system of claim 34, wherein the erdafitinib L-lactate is present in the drug formulation at a concentration of 70% by weight.

36. A drug delivery system according to any one of claims 1 to 35, wherein the drug formulation is in the form of a plurality of mini-tablets.

37. The drug delivery system of claim 36, wherein the drug formulation is in the form of about 10 to about 100 mini-tablets.

38. according to claim 36 or 37 described drug delivery system, wherein (a) described preparation comprises the mini-tablet of total length being about 14.5cm to about 15cm, and / or (b) described preparation comprises the mini-tablet of about 920mg to about 965mg, or the mini-tablet of about 920mg to about 950mg.

39. The drug delivery system according to any one of claims 1 to 38, wherein the drug delivery system is configured to release the Erdafitinib through the one or more openings in the elongated body by osmotic pressure.

40. The drug delivery system of any one of claims 1 to 39, wherein the elongate body comprises an annular wall structure defining a drug reservoir lumen, the drug formulation being disposed in the drug reservoir lumen.

41. The drug delivery system of claim 40, wherein the annular wall structure has a thickness of about 0.1 mm to about 0.5 mm.

42. The drug delivery system of claim 41, wherein the annular wall structure has a thickness of about 0.2 mm.

43. The drug delivery system according to any one of claims 40 to 42, further comprising a first end plug positioned at the first end of the annular wall structure and a second end plug positioned at the second end of the annular wall structure.

44. The drug delivery system of any one of claims 40 to 43, wherein the one or more openings in the elongated body comprise a single hole in the annular wall structure, and the elongated body is configured to release the erdafitinib through the hole.

45. The drug delivery system according to any one of claims 40 to 44, wherein the elongated body is configured to release the Erdafitinib through microchannels transiently formed at one or both end regions of the annular wall structure.

46. ​​The drug delivery system of any one of claims 1 to 45, wherein the system is configured to release the erdafitinib at an average rate of 1 mg / day to 10 mg / day.

47. The drug delivery system of any one of claims 1 to 45, wherein the system is configured to release the erdafitinib at an average rate of 1 mg / day to 6 mg / day.

48. The drug delivery system of any one of claims 1 to 45, wherein the system is configured to release the erdafitinib at an average rate of 2 mg / day to 4 mg / day.

49. The drug delivery system of any one of claims 1 to 45, wherein the system is configured to release the erdafitinib at an average rate of 4 mg / day.

50. The drug delivery system of any one of claims 1 to 50, wherein the system is configured to release the erdafitinib at an average rate of 2 mg / day.

51. The drug delivery system of any one of claims 1 to 50, wherein the system is configured to release the Erdafitinib in a zero-order release profile.

52. The drug delivery system of any one of claims 46 to 51, wherein the system is configured to release the erdafitinib for up to about 30 days.

53. The drug delivery system of any one of claims 46 to 51, wherein the system is configured to release the erdafitinib for up to about 90 days.

54. The drug delivery system according to any one of claims 1 to 53, wherein the system comprises 500 mg of the erdafitinib (free base equivalent).

55. A drug delivery system according to any one of claims 1 to 54, wherein the system is capable of elastically deforming between a relatively straightened deployment shape suitable for insertion through a patient's urethra and into the patient's bladder and a retention shape suitable for retaining the system within the bladder.

56. according to any one of claims 1 to 55 drug delivery system, wherein the system is capable of elastic deformation and comprises a tube with two relative free ends, the two relative free ends are guided away from each other when the system is in a low profile deployment shape and are guided towards each other when the system is in a relatively expanded retention shape.

57. A drug delivery system according to any one of claims 1 to 56, wherein the system comprises an elastically deformable elongated body having two opposing free ends located within the boundaries of a bi-oval-like extended retention shape.

58. The drug delivery system of any one of claims 1 to 57, wherein the elongated body further comprises a retention frame lumen.

59. The drug delivery system of claim 58, further comprising a nitinol wire disposed in the retention frame lumen.

60. A compound, which is erdafitinib lactate.

61. The compound of claim 60, which is erdafitinib L-lactate.

62. The compound of claim 61, which is erdafitinib mono-L-lactate.

63. A pharmaceutical composition comprising erdafitinib L-lactate and one or more pharmaceutical excipients.

64. The pharmaceutical composition of claim 63, wherein the at least one pharmaceutical excipient comprises or is selected from a solubilizer, a binder, a diluent (filler), a wetting agent, a disintegrant, a glidant, a lubricant, a formaldehyde scavenger, an osmotic agent, or any combination thereof.

65. The pharmaceutical composition of claim 63, wherein the at least one pharmaceutical excipient comprises or is selected from a binder, a diluent (filler), a glidant, a lubricant, or any combination thereof.

66. The pharmaceutical composition of claim 65, wherein the binder comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (PVP), vinylpyrrolidone-vinyl acetate (PVP-VA), or a combination thereof.

67. The pharmaceutical composition of claim 65 or 66, wherein the binder is present in the pharmaceutical formulation at a total concentration of about 1 wt % to about 30 wt %, about 5 wt % to about 20 wt %, or about 10 wt % to about 15 wt %.

68. A pharmaceutical composition according to any one of claims 65 to 67, wherein the diluent (filler) comprises microcrystalline cellulose, silicified microcrystalline cellulose, calcium hydrogen phosphate, or a combination thereof.

69. A pharmaceutical composition according to any one of claims 65 to 68, wherein the diluent (filler) is present in the pharmaceutical formulation at a total concentration of about 5% to about 30% by weight, about 10% to about 30% by weight, or about 10% to about 20% by weight.

70. The pharmaceutical composition according to claims 65 to 69, wherein the glidant comprises hydrophilic colloidal silicon dioxide or hydrophobic colloidal silicon dioxide, in particular hydrophilic colloidal silicon dioxide.

71. The pharmaceutical composition of any one of claims 65 to 70, wherein the glidant is present in the pharmaceutical formulation at a total concentration of about 0.05 wt % to about 1 wt %, about 0.1 wt % to about 0.5 wt %, or about 0.25 wt %.

72. A pharmaceutical composition according to any one of claims 65 to 71, wherein the lubricant comprises magnesium stearate or sodium stearyl fumarate or polyethylene glycol.

73. A pharmaceutical composition according to any one of claims 65 to 71, wherein the lubricant comprises magnesium stearate.

74. The pharmaceutical composition of any one of claims 65 to 73, wherein the lubricant is present in the pharmaceutical formulation at a total concentration of about 0.05 wt % to about 5 wt %, about 1 wt % to about 5 wt %, or about 2.5%.

75. The pharmaceutical composition according to any one of claims 65 to 74, wherein the pharmaceutical formulation comprises an intragranular composition comprising erdafitinib or a pharmaceutically acceptable salt thereof, in particular a lactate salt of erdafitinib, and at least one intragranular excipient; and an extragranular composition comprising at least one extragranular excipient.

76. The pharmaceutical composition of claim 75, wherein the at least one intragranular excipient and the at least one extragranular excipient do not comprise a common pharmaceutical excipient.

77. The pharmaceutical composition of claim 75 or 76, wherein the at least one intragranular excipient comprises an intragranular binder.

78. The pharmaceutical composition of claim 77, wherein the intragranular binder comprises hydroxypropyl methylcellulose.

79. A pharmaceutical composition according to any one of claims 75 to 78, wherein the at least one extragranular excipient comprises one or more of an extragranular binder, an extragranular filler (diluent), an extragranular glidant, and an extragranular lubricant.

80. The pharmaceutical composition of claim 79, wherein the extragranular binder comprises vinyl pyrrolidone-vinyl acetate.

81. The pharmaceutical composition of claim 79 or 80, wherein the extragranular diluent (filler) comprises microcrystalline cellulose, silicified microcrystalline cellulose, or a combination thereof.

82. A pharmaceutical composition according to any one of claims 79 to 81, wherein the extragranular glidant comprises hydrophilic colloidal silicon dioxide.

83. A pharmaceutical composition according to any one of claims 79 to 82, wherein the extragranular lubricant comprises magnesium stearate or sodium stearyl fumarate or polyethylene glycol.

84. A pharmaceutical composition according to any one of claims 79 to 83, wherein the extragranular lubricant comprises magnesium stearate.

85. The pharmaceutical composition of any one of claims 63 to 84, wherein the erdafitinib L-lactate is present in the pharmaceutical formulation at a concentration of 60 wt% to 91 wt% or 60 wt% to 80 wt%.

86. The pharmaceutical composition of claim 85, wherein the erdafitinib L-lactate is present in the pharmaceutical formulation at a concentration of 70% by weight.

87. A pharmaceutical composition according to any one of claims 63 to 86, wherein the composition is in the form of a tablet.

88. The pharmaceutical composition of claim 87, wherein the tablet is a mini-tablet.

89. The pharmaceutical composition of claim 87 or 88, wherein the tablet has a hardness of at least about 100N.

90. The pharmaceutical composition of claim 89, wherein the tablet has a hardness of about 150N to about 250N.

91. The pharmaceutical composition of claim 89, wherein the tablet has a hardness of about 175N to about 225N.

92. The pharmaceutical composition of any one of claims 87 to 91, wherein the tablet has a thickness of about 3.2 mm to about 3.6 mm.

93. A method for preparing a pharmaceutical composition in tablet form, comprising: (a) preparing a solid composition within the granules, the solid composition within the granules comprising: (i) Erdafitinib L-lactate; and (ii) at least one intragranular pharmaceutical excipient; (b) combining the intragranular solid composition with at least one extragranular pharmaceutical excipient to form a blend; and (c) tableting the blend to form the solid pharmaceutical composition.

94. The method for preparing a solid pharmaceutical composition according to claim 93, wherein: (a) the at least one intragranular pharmaceutical excipient comprises at least one intragranular binder; and (b) The at least one extragranular pharmaceutical excipient comprises an extragranular binder, an extragranular filler (diluent), an extragranular glidant and an extragranular lubricant.

95. The method for preparing a tablet according to claim 93 or 94, wherein the intragranular solid composition is prepared by a fluidized bed granulation method.

96. A process for preparing a solid pharmaceutical composition according to claim 94 or 95, wherein the at least one intragranular binder comprises hydroxypropyl methylcellulose.

97. A process for preparing a solid pharmaceutical composition according to any one of claims 94 to 96, wherein the at least one extragranular binder comprises vinyl pyrrolidone-vinyl acetate (PVP VA).

98. A process for the preparation of a solid pharmaceutical composition according to any one of claims 94 to 97, wherein the at least one extragranular filler (diluent) comprises microcrystalline cellulose.

99. The method for preparing a solid pharmaceutical composition according to claim 98, further comprising a second extragranular filler (diluent), wherein the second extragranular filler (diluent) comprises silicified microcrystalline cellulose.

100. A process for preparing a solid pharmaceutical composition according to any one of claims 94 to 99, wherein the extragranular glidant comprises hydrophilic colloidal silicon dioxide.

101. A process for preparing a solid pharmaceutical composition according to any one of claims 94 to 100, wherein the extragranular lubricant comprises magnesium stearate.

102. A method for preparing a solid pharmaceutical composition according to any one of claims 94 to 100, wherein the extragranular lubricant comprises sodium stearyl fumarate.

103. A method for preparing a solid pharmaceutical composition according to any one of claims 93 to 102, wherein the ejection force is less than about 1000N.

104. A pharmaceutical composition according to claim 88, wherein the mini-tablet is in the form of a solid cylinder having a cylindrical axis, a cylindrical side, a circular end face perpendicular to the cylindrical axis, a diameter passing through the circular end face, and a length along the cylindrical side face.

105. A solid pharmaceutical composition according to claim 104, wherein the length of the microtablet exceeds the diameter of the microtablet to provide the microtablet with an aspect ratio (length:diameter) greater than 1:

1.

106. The solid pharmaceutical composition of claim 104 or 105, wherein the mini-tablet has a diameter of 1.0 mm to 3.2 mm, or 1.5 mm to 3.1 mm.

107. A solid pharmaceutical composition according to claim 104 or 105, wherein the mini-tablet has a diameter of 2.5 mm to 2.7 mm.

108. A solid pharmaceutical composition according to any one of claims 104 to 107, wherein the minitablet has a length of 3.0 mm to 3.5 mm.

109. A solid pharmaceutical composition according to any one of claims 104 to 108, wherein the mini-tablet has a mass of 22 mg to 24 mg.

110. The drug delivery system according to any one of claims 44 to 59, wherein the elongated body is configured to release the Erdafitinib through the hole and through a microchannel transiently formed at one end region of the annular wall structure.

111. The drug delivery system according to any one of claims 44 to 59, wherein the elongated body is configured to release the Erdafitinib through the hole and through microchannels transiently formed at both end regions of the annular wall structure.

112. A drug delivery system according to any one of claims 45, 110 or 111, wherein the microchannel is formed instantaneously when the osmotic pressure increases above a certain threshold.